

Final Program

7 | 10
SEPTEMBER
2022

15TH
ROME

INTERNATIONAL SYMPOSIUM ON
Sjögren's
Syndrome

Chairperson of the Congress: Prof. Salvatore De Vita
Clinic of Rheumatology, University of Udine - Udine, Italy





This course is endorsed by EULAR



Patronages



WELCOME LETTER

It is an honor for Italy to host the "15th International Symposium on Sjögren's Syndrome". The Congress comes back to Italy for the second time after the edition held in Venice on December 1999.

The Symposium was proposed on behalf of GRISS (Italian Research Group on Sjögren's Syndrome) and SIR (Società Italiana di Reumatologia – the Italian Society of Rheumatology), with the hope of encouraging scientific research and interaction especially between younger colleagues, from Italy and from countries abroad.

We are confident that the Symposium will be useful to all attendees, to improve the clinical and scientific progress, to better focus future research and therefore patient care.

The program covers recent developments in pathogenesis, clinical assessment with stratification, lymphoproliferation, and personalized medicine. The discussion will also focus on the nomenclature of Sjögren's Syndrome and the implications of COVID-19 infection, still present worldwide.

The focus is on the evaluation and understanding of the pathogenesis of Sjögren's Syndrome associated with other autoimmune diseases, and on how different medical specialists and primary care physicians can better coordinate with each other in dealing with patients and in the field of research.

The needs and opinions of patients will be another key topic of discussion, with the participation of representatives from European and US Associations, with different health policies applying in different countries.

Discussion will be also about recent developments in treatment and testing of new drugs, along with International cooperative research, which is also extremely important.

Welcome everybody to the Symposium and to Rome! We hope this will be a profitable experience and that you will be able to enjoy the Eternal City and this wonderful country!

Salvatore De Vita
Chairperson of the Congress



Luca Quartuccio
Young Co-Chairman



Chiara Baldini
Young Co-Chairman



CHAIRPERSON OF THE CONGRESS

Salvatore De Vita, Italy

YOUNG CO-CHAIRMEN

Chiara Baldini, Italy

Luca Quartuccio, Italy

SCIENTIFIC COMMITTEE

A. Baer, USA

C. Baldini, Italy

E. Bartoloni Bocci, Italy

S. Bombardieri, Italy

M. Bombardieri, UK

H. Bootsma, The Netherlands

S.J. Bowman, UK

L.A. Criswell, USA

S. De Vita, Italy

T. Dörner, Germany

C. Fabro, Italy

R.I. Fox, USA

V. Manfrè, Italy

X. Mariette, France

J.O. Pers, France

L. Quartuccio, Italy

M. Ramos Casals, Spain

E. Treppo, Italy

A.G. Tzioufas, Greece

A. Zabotti, Italy

LOCAL ORGANIZING COMMITTEE

L. Quartuccio, Italy

A. Zabotti, Italy

E. Treppo, Italy

V. Manfrè, Italy

C. Fabro, Italy

E. Bartoloni Bocci, Italy

F. Conti, Italy

R. Gerli, Italy

R. Priori, Italy

G. Valesini, Italy

C. Vitali, Italy

WORKING TEAM

S. De Vita, Italy

S. Bombardieri, Italy

A.G. Tzioufas, Greece

H. Bootsma, The Netherlands

C. Baldini, Italy

E. Bartoloni Bocci, Italy

M. Bombardieri, UK

M. Ramos-Casals, Spain

T. Dörner, Germany

and consultants

A. Baer, USA

S.J. Bowman, UK

L.A. Criswell, USA

R.I. Fox, USA

X. Mariette, France

J.O. Pers, France

INTERNATIONAL ADVISORY BOARD - PAST PRESIDENTS

A. Baer, USA

S. Bombardieri, Italy

P. Fox, USA

R. Jonsson, Norway

H.M. Moutsopoulos, Greece

A. Parke, USA

J.O. Pers, France

T. Sumida, Japan

A.G. Tzioufas, Greece

P. Youinou, France

INTERNATIONAL COMMITTEE

J.M. Anaya, Colombia

E.K. Akpek, USA

M. Bombardieri, UK

H. Bootsma, The Netherlands

S.J. Bowman, UK

S. Carsons, USA

L.A. Criswell, USA

C.S. De Paiva, USA

T. Dörner, Germany

B.A. Fisher, UK

A.V. Goules, Greece

J.E. Gottenberg, France

S.I. Kwok, Korea

L. Lu, China

X. Mariette, France

T. Mandl, Sweden

C.P. Mavragani, Greece

R. Omdal, Norway

H. Park, Korea

S.C. Plugfelder, USA

M. Ramos-Casals, Spain

S. Retamozo, Spain

L. Ronblom, Sweden

A. Rosen, USA

H.A. Saraux, France

H. Scofield, USA

S.C. Shiboski, USA

M. Tomsic, Slovenia

J. Van Roon, The Netherlands

A. Vissink, The Netherlands

F.B. Vivino, USA

M. Wahren-Herlenius, Sweden

W.F. Ng, UK



INDEX

SCIENTIFIC PROGRAM	P. 7
Wednesday 7 September	p. 8
Thursday 8 September	p. 9
Friday 9 September	p. 14
Saturday 10 September	P. 20
NO UEMS SESSIONS	P. 22
Wednesday 7 September	p. 24
Saturday 10 September	P. 25
POSTERS	P. 27
INFORMATION	P. 49
TIPS WHEN IN ROME	P. 52
AUTHORS INDEX	P. 56
SPONSORS ACKNOWLEDGEMENT	P. 63





SCIENTIFIC PROGRAM



WEDNESDAY 7 SEPTEMBER

S. Francesco Room

14.30-17.45



PRELIMINARY COURSE ULTRASONOGRAPHY OF THE MAJOR SALIVARY GLANDS IN SJÖGREN'S SYNDROME
(see page 24)

Auditorium

18.15-18.30

OPENING CEREMONY



S. De Vita (Italy), S. Bombardieri (Italy), R. Gerli (Italy)

18.30-19.00

MAIN LECTURE

Autoimmunity and infections in marginal zone B-cell lymphomas

M. Ponzoni (Italy)

19.00

Welcome Reception



speaker/chairman remotely connected




THURSDAY 8 SEPTEMBER

Auditorium

1. EVOLVING TOPICS IN pSS PATHOGENESIS

Chairs: M. Bombardieri (UK), F.G.M. Kroese (The Netherlands)

- 08.10-08.20 **Properties of epithelial cells**
E. Kapsogeorgou (Greece)
- 08.20-08.30  **Infection and the salivary epithelium**
M. Wahren-Herlenius (Sweden)
- 08.30-08.40 **Interaction of epithelium with immune cells**
G. Nocturne (France)
- 08.40-08.50 **Discussion**
- 08.50-09.08 **Innate immunity**
M.A. Versnel (The Netherlands)
- 09.08-09.24 **B-cells in benign lesions**
G.M. Verstappen (The Netherlands)
- 09.24-09.42 **Autoantibodies**
T. Witte (Germany)
- 09.42-10.10 **T cells and co-stimulation**
M. Bombardieri (UK)
- 10.10-10.18 **Key findings of genetics and epigenetics**
C.J. Lessard (USA)



speaker/chairman remotely connected



THURSDAY 8 SEPTEMBER

- 10.18-11.07** **SELECTED ORAL PRESENTATIONS**
- 10.18-10.25 **Long non-coding RNA HCP5 is a key regulator of CDC2S function: implications for Sjögren's Syndrome**
A. Pinheiro Lopes (The Netherlands)
- 10.25-10.32 **Transcriptome-wide association study of Sjögren's disease risk alleles identifies novel genes with altered expression in minor salivary gland and other tissues**
C.J. Lessard (USA)
- 10.32-10.39 **Single cell and spatial transcriptomics identifies altered cellular neighborhoods in the salivary glands of Sjögren's disease patients**
W. Blake (USA)
- 10.39-10.46 **Harnessing cell energy metabolism to suppress salivary gland inflammation in Sjögren's Syndrome**
S. Colafrancesco (Italy)
- 10.46-10.53 **Single-cell RNA sequencing data from the sicca collection differentiate Sjögren's disease and elucidate cellular patterns of composition and expression**
K. Taylor (USA)
- 10.53-11.00 **Identification of Sjögren's disease-associated t cell receptors through deep sequencing and single-cell approaches**
A.A. Jupudi (USA)
- 11.00-11.07 **Baff-Var is a new predisposing factor for pSS and impacts disease activity**
M. Dulin (France)
- 11.07-11.25* *Coffee break*



THURSDAY 8 SEPTEMBER

2. EVOLVING TOPICS IN pSS STRATIFICATION

Chairs: A. Baer (USA), A.G. Tzioufas (Greece)

The Clinical picture

11.25-11.42 **The different clinical phenotypes of pSS**
A.V. Goules (Greece)

Laboratory for stratification

11.42-12.00 **Biological markers for stratification in pSS**
J.O. Pers (France)

12.00-12.12 **Transcriptomic analysis in different cohorts**
J.E. Gottenberg (France)

12.12-12.24 **SICCA NextGen: Preliminary Omics Analyses**
G. Urbanski (USA)

Salivary Imaging and biopsy for stratification

12.24-12.39 **Imaging biomarkers for stratification**
C. Baldini (Italy)

12.39-12.51 **Labial minor salivary gland biopsy**
B.A. Fisher (UK)

12.51-13.01 **Surgical parotid biopsy**
A. Vissink (The Netherlands)

13.01-13.11 **US-guided parotid and submandibular biopsy:
accuracy and safety**
A. Zabotti (Italy)


13.11-14.15 **Lunch and Poster tour**
*The Posters' Authors are kindly requested to stand by their poster's
board and be available for discussion*



THURSDAY 8 SEPTEMBER

3. EVOLVING TOPICS IN pSS-RELATED LYMPHOPROLIFERATION

Chairs: G. Ferraccioli (Italy), X. Mariette (France)

- 14.15-14.30 **Clinical features of lymphoma updated**
A.G. Tzioufas (Greece)
- 14.30-14.45  **The importance of the parotid study in pSS and lymphoma genesis**
S. De Vita (Italy)
- 14.45-15.00 **Local networks and oncogenetic events in B cell expansion: crucial events and perspectives**
J. Reed (Australia)
- 15.00-15.15 **Predicting lymphoma in pSS today**
X. Mariette (France)

The use of parotid biopsy in pSS...

- 15.15-15.22 **...for salivary gland swelling or suspect areas**
A. Zabotti (Italy)
- 15.22-15.29 **...for the diagnosis of pSS: YES**
T. Dörner (Germany)
- 15.29-15.36 **...for the diagnosis of pSS: NO**
M. Voulgarelis (Greece)
- 15.36-15.43 **...for both**
H. Bootsma (The Netherlands)
- 15.43-15.50 **Discussion**

15.50-16.05 *Coffee break*

16.05-17.15 **SELECTED ORAL PRESENTATIONS**


- 16.05-16.12 **Cytokine/chemokine expression in primary Sjögren's Syndrome patients**
L. Chatzis (Greece)
- 16.12-16.19 **Natural history of Sjögren's disease from the national institutes of health cohort**
B. Law (USA)



speaker/chairman remotely connected



THURSDAY 8 SEPTEMBER

- 16.19-16.26 **Transitional CD5+ B cells are associated with autoreactivity in pSS patients**
L. Chatzis (Greece)
- 16.26-16.33  **The University of Florida Cohort with childhood Sjögren's disease classified by the latent class analysis**
W. Zeng (USA)
- 16.33-16.40 **Multi-modal analysis supports IL-7/IL-7 receptor axis as a relevant target in Sjögren's Syndrome**
E. Desvaux (France)
- 16.40-16.47 **Symptom-based clustering in Sjögren's Syndrome: a clue for investigating pathobiological non inflammatory mechanisms of the disease**
C. Baldini (Italy)
- 16.47-16.54 **The analysis of macrophage tissue heterogeneity in the salivary glands of patient with primary Sjögren's Syndrome reveals novel players in the lymphomagenesis of the disorder**
M. Manoussakis (Greece)
- 16.54-17.01 **Lymphoma associated risk factors in primary Sjögren's Syndrome by data driven analysis in harmonized patients**
A.V. Goules (Greece)
- 17.01-17.08 **The value of FDG-PET/CT in the detection of lymphomas associated with primary Sjögren's Syndrome**
M.S Van Ginkel (The Netherlands)
- 17.08-17.15 **Value of UHFUS in the diagnostic work up and guided biopsy of suspected labial salivary gland lymphoproliferative lesions in Sjögren's Syndrome**
G. Fulvio (Italy)



speaker/chairman remotely connected



FRIDAY 9 SEPTEMBER

4. EVOLVING TOPICS IN THE EVALUATION OF pSS

Chairs: H. Bootsma (The Netherlands), A.V. Goules (Greece)

Platforms to collect data: built ad hoc or pre-formed/adapted?

08.20-08.28  **The Harmonicss experience**
T.P. Exarchos (Greece)

08.28-08.36 **The Necessity experience**
M. Barnes (UK)

08.36-08.40 **Discussion**

Integration between doctors and engineers using artificial Intelligence

08.40-08.48 **The physician point of view**
C.P. Mavragani (Greece)

08.48-08.56 **The engineer point of view**
D.I. Fotiadis (Greece)

08.56-09.00 **Discussion on the topic above**

09.00-09.20 **Activity and damage**
H. Bootsma (The Netherlands)

09.20-09.40 **Composite indexes and STAR (Sjögren Tool for Assessing Response to treatment) for using in clinical trials**
R. Seror (France)

09.40-09.55 **Focused clinical endpoints vs. trial endpoints**
L. Quartuccio (Italy)

09.55-10.10 **Evaluation of the disease-related component of chronic pain and fatigue**
W.F. Ng (UK)



speaker/chairman remotely connected



FRIDAY 9 SEPTEMBER

- 10.10-10.45** **SELECTED ORAL PRESENTATIONS**
- 10.10-10.17 **Novel autoantibodies identified in seronegative Sjögren's using innovative whole peptidome array technology**
S. McCoy (USA)
- 10.17-10.24 **Identification of a saliva exosomal-RNA signature for Sjögren's Syndrome**
A. Papas (USA)
- 10.24-10.31 **Cell type-specific dysregulation found to differentiate patient subsets of Sjögren's disease**
C.J. Lessard (USA)
- 10.31-10.38 **The usefulness of ultrasound-guided core needle biopsy of the parotid gland for the diagnosis of primary Sjögren's Syndrome**
V. Manfrè (Italy)
- 10.38-10.45 **Ultrasound scoring systems affect the distribution of sialadenitis scores in Sjögren's Syndrome: an inter-system reproducibility study**
G. Cafaro (Italy)
- 10.45-11.05* *Coffee break*



FRIDAY 9 SEPTEMBER

**5. ASSOCIATION OF SS WITH OTHER AUTOIMMUNE DISEASES:
IMPLICATIONS FOR DISEASE BIOLOGY AND MANAGEMENT**

Chairs: T. Dörner (Germany), R. Gerli (Italy)

- 11.05-11.20 **pSS, SLE and UCTD**
A. Doria (Italy)
- 11.20-11.35 **pSS with autoimmune thyroid disease or coeliac disease**
R. Gerli (Italy)
- 11.35-11.50 **pSS with SSc**
N. Del Papa (Italy)
- 11.50-12.05 **pSS with RA**
G. Nocturne (France)
- 12.05-12.16 **Polyautoimmunity in Sjögren's Syndrome**
J.M. Anaya Cabrera (Colombia)

12.16-12.30 SELECTED ORAL PRESENTATIONS

- 12.16-12.23 **Single cell Atlas of minor salivary glands reveals key differential cellular and functional players in Sjögren's and sicca Syndrome**
S. Nayar (UK)
- 12.23-12.30 **Characterization of the muscle inflammatory infiltrate by Hyperion technology in inclusion myositis associated with Sjögren's Syndrome, comparison with sporadic forms**
B. Quéré (France)



FRIDAY 9 SEPTEMBER

6. THE NOMENCLATURE OF SS

Chairs:  S. De Vita (Italy), A.G. Tzioufas (Greece)

12.30-12.35

Introduction

A.G. Tzioufas (Greece)

12.35-12.47

Sjögren Syndrome vs Sjögren disease

A. Baer (USA)

12.47-13.00

Secondary vs. Associated Sjögren

P. Brito-Zerón (Spain)

13.00-13.30

Round table with experts and plenary discussion

13.30-14.30

Lunch and Poster tour

The Posters' Authors are kindly requested to stand by their poster's board and be available for discussion


7. THE INVOLVEMENT OF DIFFERENT SPECIALITIES IN THE CARE OF SS

Chairs: F. Conti (Italy),  J. Barrio Cortes (Spain)

14.30-14.45

New developments in the management of dry mouth

M. Jonsson (Norway)

14.45-15.00 

Extraglandular ocular findings of Sjögren's Syndrome

E.K. Akpek (USA)

Pediatric pSS

15.00-15.15


Clinical manifestations

S. Retamozo (Spain)

15.15-15.30


Recurrent parotitis, US and parotid biopsy in children

A. Tommasini (Italy)

 speaker/chairman remotely connected



FRIDAY 9 SEPTEMBER

- 15.30-15.40 **seXX matters in Sjögren's Syndrome**
R. Priori (Italy)
- 15.40-15.50  **Migraine headache and pSS**
R.I. Fox (USA)
- 15.50-16.00 **Concomitant causes of fatigue and chronic pain in pSS**
P. Sarzi Puttini (Italy)
- 16.00-16.10 **Organization of referral pathways in specialized centers**
E. Bartoloni Bocci (Italy)
- 16.10-16.20 **Future improvements proposed by European Rare Disease
Network ReCONNECT**
M. Mosca (Italy)
- 16.20-16.41 SELECTED ORAL PRESENTATIONS**
- 16.20-16.27 **Outcome of pregnancy in women with primary Sjögren's
Syndrome compared to the general population: the French
multicenter prospective GR2 study**
G. Frémont (France)
- 16.27-16.34 **Salivary flow rate and oral status in patients with primary
Sjögren Syndrome and diffuse cutaneous systemic sclerosis:
a cross-sectional study**
M. Radic (Croatia)
- 16.34-16.41 **Ultra-high frequency ultrasonography of labial glands in
pediatric Sjögren's Syndrome: a preliminary study**
E. Marrani (Italy)
- 16.41-17.00 *Coffee break*



FRIDAY 9 SEPTEMBER

8. pSS AND COVID-19 INFECTION

Chairs: L. Quartuccio (Italy), C. Vitali (Italy)

- 17.00-17.15  **Autoimmunity and COVID-19**
M. Galli (Italy)
- 17.15-17.30 **Sjögren's Syndrome and COVID-19**
P. Brito-Zerón (Spain)
- 17.30-18.20 SELECTED ORAL PRESENTATIONS**
- 17.30-17.37 **Safety and efficacy of Sars-Cov-2 vaccination in 1237 patients with primary Sjögren's Syndrome**
N. Inanc (Turkey)
- 17.37-17.44 **Sars-Cov-2 induces a Sjögren's Syndrome-like phenotype**
C. Nguyen (USA)
- 17.44-17.51 **Ianalumab (VAY736) safety and efficacy in patients with Sjögren's Syndrome: 52 week results from a randomized, placebo-controlled, phase 2b dose-ranging trial**
T. Dörner (Germany)
- 17.51-17.58 **Early changes in free light chains to predict ESSDAI, ESSPRI and CRESS and STAR outcomes upon leflunomide/hydroxychloroquine combination therapy**
S. Hamkour (The Netherlands)
- 17.58-18.05 **Leflunomide /hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's Syndrome that allow prediction and monitoring of clinical response**
S. Hamkour (The Netherlands)
- 18.05-18.12 **In Sjögren's Syndrome salivary glands Baricitinib downregulates inflammation via a double effect on epithelial cells and inflammatory infiltrates**
S. Colafrancesco (Italy)
- 18.12-18.19 **Sjögren's coexisting with autoimmune diseases: a systematic literature review informing the international task force of Sjögren's nomenclature and classification Rome 2022**
S. Retamozo (Spain)




speaker/chairman remotely connected



SATURDAY 10 SEPTEMBER

9. EVOLVING TOPICS IN pSS THERAPY



Chairs: S.J. Bowman (UK), C.H. Shiboski (USA)

- 08.30-08.50 **Current recommendations and unmet needs**
M. Ramos-Casals (Spain)
- 08.50-09.05 **INPUTS from trials**
S. Bowman (UK)
- 09.05-09.15 **Selection of patients and endpoints for clinical trials**
S. Arends (The Netherlands)
- 09.15-09.30 **Developing novel therapies for patients with Sjögren's Syndrome:
the pharma perspective**
G. Illei (USA)
- 09.30-10.45  **New therapies in the pipeline**
(see page 25)

10.45-11.05 *Coffee break*


10. EVOLVING TOPICS IN HEALTH POLICIES

Chairs: C. Baldini (Italy), S. Bombardieri (Italy)

- 11.05-11.17  **Geographic variation in the management of pSS in Europe**
C. Seghieri (Italy)
- 11.17-11.29  **pSS and the general practitioner**
J. Barrio Cortes (Spain)

Patients' needs and health policies

- 11.29-11.41 **Sjögren Europe EULAR PARE patient federation?**
A. Vieira (Portugal)
- 11.41-11.55 **SSF USA**
K.M. Hammitt (USA)

 *speaker/chairman remotely connected*



SATURDAY 10 SEPTEMBER

11. EVOLVING TOPICS IN COOPERATIVE RESEARCH

Chairs: M. Ramos-Casals (Spain), A.G. Tzioufas (Greece)

- 11.55-12.05 **ERN Reconnect**
M. Mosca (Italy)
- 12.05-12.15 **A new multi-center US Sjögren disease research collaboration**
C.H. Shiboski (USA)
- 12.15-12.25 **Big Data**
M. Ramos-Casals (Spain)
- 12.25-12.35 **PRECISESADS**
J.O. Pers (France)
- 12.35-12.45 **HarmonicSS**
A.V. Goules (Greece)
- 12.45-12.55 **Necessity**
X. Mariette (France)
- 12.55-13.05 **Essential**
A.G. Tzioufas (Greece)
- 13.05-13.15 **Sjögren's Genetics Network (SGENE)**
C.J. Lessard (USA)

13.15-13.45 Closing remarks and Poster Awards





NO UEMS SESSION



NO UEMS SESSIONS

**NO
UEMS**

Wednesday 7 September

S. Francesco Room

14.30-17.45 PRELIMINARY COURSE ULTRASONOGRAPHY OF THE MAJOR SALIVARY GLANDS IN SJÖGREN'S SYNDROME

14.30 **Introduction and course objectives**
A. Zabotti (Italy)

The role of Salivary Gland Ultrasonography (SGUS) in primitive Sjögren's Syndrome (pSS) patients

Chairman: G.A.W. Bruyn (The Netherlands), S. Jousse-Joulin (France)

14.45-15.00 **The role of SGUS in the diagnosis of pSS**
K. Delli (The Netherlands)

15.00-15.15 **The role of SGUS in the prognosis and follow-up of pSS**
C. Baldini (Italy), F. Ferro (Italy)

15.15-15.30 **The role of SGUS for the differential diagnosis of pSS**
C. Dejacco (Italy)

15.30-15.45 **The role of Color Doppler in the SGUS**
A. Hocevar (Slovenia)

15.45-16.00 **The sonographic features of lymphoma in pSS patients**
M. Lorenzon (Italy), I. Giovannini (Italy)

Live demonstration

Chairman: G.A.W. Bruyn (The Netherlands), S. Jousse-Joulin (France), M. Jonsson (Norway), A. Zabotti (Italy)

16.00-16.30 **Standard scans and normal anatomy of the major salivary glands**
A. Gattamelata (Italy), L. Navarini (Italy)

16.30 - 17.30 **Hands on in pSS patients**
Supervisors: A. Gattamelata (Italy), L. Navarini (Italy), K. Delli (The Netherlands), A. Stel (The Netherlands)

17.30-17.45 **Take home messages**
A. Zabotti (Italy)



NO UEMS SESSIONS

**NO
UEMS**

Saturday 10 September

Auditorium

09.30-10.45

NEW THERAPIES IN THE PIPELINE

09.30-09.45

Horizon Therapeutics: Moving Science Forward for Rare, Autoimmune and Severe Inflammatory Diseases
I. Alevizos (USA)

09.45-10.00

Reduction of Sjögren's autoantibodies by blocking IgG recycling through the neonatal Fc Receptor (FcRN)
K. Sivils (USA)

10.00-10.45

Discussion





POSTERS

Please note that the abstract book is ordered by topic and the numbering corresponds to the submission ID, while the numbering of the posters in the final program follows the poster board number. Please refer to the title of the abstract to look for the entire text of the work



POSTER

1. EVOLVING TOPICS IN pSS PATHOGENESIS

PO1:01 EXPLORATION OF THE CELLULAR MICROENVIRONMENT IN MINOR SALIVARY GLANDS OF PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME BY IMAGING MASS CYTOMETRY

Bharaj T.*¹, Helgesen Y., Fromreide S., Borge H., Brokstad K., Cox R., Tornaas S., Brun J.G., Jonsson R., Bergum B., Appel S., Skarstein K.
Bergen, Norway

PO1:02 CCL5 RELEASE BY CCR9+ CD8 T CELLS: A POTENTIAL NOVEL CONTRIBUTOR TO IMMUNOPATHOLOGY OF PRIMARY SJÖGREN'S SYNDROME

Hinrichs A., Blokland S., Kruize A., Lafeber F., Leavis H., Van Roon J.*
Utrecht, The Netherlands

PO1:03 B CELL GLYCOSYLATION IN PRIMARY SJÖGREN'S SYNDROME: A NEW POTENTIAL BIOMARKER.

Morel M.*¹, Pochard P., Dueymes M., Bagacean C., Jousse-Joulin S., Devauchelle-Pensec V., Jamin C., Pers J.O., Cornec D., Bordron A.
Brest, France

PO1:04 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN A COHORT OF PRIMARY SJÖGREN'S SYNDROME PATIENTS: A NOVEL MARKER OF DISEASE ACTIVITY?

Cafaro G.*¹, Bianconi V., Perricone C., Cosentini E., Riccucci I., Mannarino M.R., Pirro M., Gerli R., Bartoloni E.
Perugia, Italy

PO1:05 DECIPHERING THE ROLE OF CDC25 IN SJÖGREN'S SYNDROME: TRANSCRIPTOMIC PROFILE LINKS ALTERED ANTIGEN PROCESSES WITH IFN-SIGNATURE AND AUTOIMMUNITY

Lopes A.*¹, Hillen M., Hinrichs A., Blokland S., Bekker C., Pandit A., Kruize A., Radstake T., Van Roon J.
Utrecht, The Netherlands

PO1:06 SINGLE CELL RNA SEQUENCING POINTS TO A ROLE FOR FIBROBLASTS EARLY IN SALIVARY GLAND DYSFUNCTION IN PRIMARY SJÖGREN'S SYNDROME

Pringle S.*¹, Berg M., Spijkervet F., Vissink A., Bootsma H., Kroese F.G.M.
Groningen, The Netherlands

PO1:07 ABNORMALITIES OF EXTRACELLULAR MATRIX MODELING GENE EXPRESSION IN SALIVARY GLAND EPITHELIAL CELLS OF PATIENTS WITH SJÖGREN'S SYNDROME

Rivière E.*¹, Pascaud J., Letourneur F., Nocturne G., Mariette X.
Paris, France

PO1:08 DEFECTIVE LOCALIZATION AND INTERACTION OF AQUAPORIN-5 INTERACTING PROTEIN PARTNERS IN SALIVARY GLANDS FROM PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME

D'Agostino C.*¹, Chivasso C.¹, Filipovic N.¹, Conrad L.¹, Zindy E.¹, Perret J.¹, Muhammad S.S.¹, Moscato S.², Baldini C.², Mattii L.², Delporte C.¹
¹Bruxelles, Belgium, ²Pisa, Italy



POSTER

PO1:09 EXPLORATORY IMMUNOPHENOTYPE OF THE RARE DISEASE JUVENILE SJÖGREN'S SYNDROME REVEALS A DYSREGULATION OF B AND T MEMORY CELL FREQUENCIES.

Martin-Gutierrez L.* , Peckham H., Radziszewska A., Peng J., Nettey O., Jury L., Ciurtin C.
London, UK

PO1:10 IMMUNE CHECKPOINT INHIBITOR TREATMENT MAY INDUCE SALIVARY GLAND PROGENITOR CELL PROLIFERATION

Pringle S.* , Van Der Vegt B., Vissink A., Bootsma H., Kroese F.G.M.
Groningen, The Netherlands

PO1:11 FINE MAPPING OF THE DDX6-CXCR5 RISK INTERVAL REVEALS SNPS IN SJÖGREN'S DISEASE WITH FUNCTIONAL SIGNIFICANCE IN IMMUNE CELLS AND SALIVARY GLAND

Wiley M.¹, Khatri B.¹, Tessneer K.¹, Joachims M.¹, Stolarczyk A.¹, Nagel A.¹, Rasmussen A.¹, Bowman S.J.², Radfar L.¹, Omdal R.³, Wahren-Herlenius M.⁴, Warner B.⁵, Witte T.⁶, Jonsson R.⁷, Rischmueller M.⁸, Gaffney P.¹, James J.A.¹, Rönnblom L.⁹, Scofield R.H.¹, Mariette X.¹⁰, Ng W.F.¹¹, Sivils K.¹², Nordmark G.⁹, Tsao B.¹³, Lessard C.J.*¹

¹Oklahoma City, USA, ²Birmingham, UK ³Stavanger, Norway, ⁴Stockholm, Sweden, ⁵BethesdaUSA, ⁶Hannover, Germany, ⁷Bergen, Norway, ⁸Adelaide, Australia, ⁹Uppsala, Sweden, ¹⁰Le Kremlin Bicêtre, France, ¹¹Newcastle Upon Tyne, UK, ¹²Spring House, USA, ¹³Charleston, USA

PO1:12 CYTOKINE MRNA DETECTION IN SALIVARY GLANDS OF PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME USING THE RNASCOPE® ISH TECHNOLOGY

Borge H.*¹, Fromreide S.¹, Aqrabi A.L.², Dongre H.¹, Galtung H.², Liaaen Jensen J.², Skarstein K.¹
¹Bergen, Norway, ²Oslo, Norway

PO1:13 LABIAL AND PAROTID SALIVARY GLAND HISTOPATHOLOGY IN PRIMARY SJÖGREN'S SYNDROME

Nakshbandi U.* , Van Ginkel M.S., Bootsma H., Liefers S.C., Spijkervet F.K., Vissink A., Van Der Vegt B., Kroese F.G.M.
Groningen, The Netherlands

PO1:14 USE OF SALIVARY AUTOANTIBODIES IN SICCA PATIENTS TO DETECT DISEASE

Tsaliki M.* , Cavett J., Kurien B., Bruxvoort C., Scofield R.H., Koelsch K.A.
Oklahoma City, USA

PO1:15 M6A METHYLATION OF RNA IN SALIVARY GLAND EPITHELIAL CELLS: ROLE IN SJÖGREN'S SYNDROME

Shalabi H., Rivière E., Pascaud J., Nocturne G., Mariette X., Bechara R.*
Le Kremlin Bicêtre, France

PO1:16 ABNORMALITY OF TYPE I INTERFERON SIGNALLING IN B CELLS IN PRIMARY SJÖGREN'S SYNDROME AND THE IMPACT ON LABORATORY AND CLINICAL FINDINGS

Ritter J., Szelsinki F.* , Aue A., Stefanski A., Schrezenmeier E., Lino A., Dörner T.
Berlin, Germany

POSTER

PO1:17 IMMUNIZATION IN PRIMARY SJÖGREN'S SYNDROME - THE IMPORTANCE OF THE CYTOKINE PROFILE IN RESPONSE TO DISEASE-MODIFYING THERAPY

Sebastian A., Madej M., Gajdanowicz P., Sebastian M., Luczak A., Zemelka-Wiacek M., Jutel M., Wiland P.*
Wrocław, Poland

PO1:18 SSA-REACTIVE B CELLS ESCAPE PERIPHERAL TOLERANCE CHECKPOINTS IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME

Chriti N., Tison A., Porchet E., Marec N., Devauchelle-Pensec V., Pers J.O., Hillion S., Cornec D.*
Brest, France

PO1:19 TARGETED METABOLOMICS IN LABIAL SALIVARY GLANDS HIGHLIGHTS NEW POTENTIAL BIOMARKERS TO PREDICT PRIMARY SJÖGREN'S SYNDROME.

Urbanski G.*¹, Chabrun F.¹, Lacout C.¹, Lozac H.P.², Blanchet O.¹, Chao De La Barca J.¹, Simard G.¹, Lavigne C.¹, Reynier P.¹
¹Angers, France, ²Le Mans, France

PO1:20 THE TUBARIAL GLANDS RESEMBLE THE PALATAL SALIVARY GLANDS BASED ON FURTHER HISTOLOGICAL CHARACTERIZATION, AND MAY REPRESENT AN ORGAN OF INTEREST IN PRIMARY SJÖGREN'S SYNDROME

Pringle S.*¹, Bikker F.², Vogel W.², Hofland I.², Van Der Vegt B.¹, Bootsma H.¹, Kroese F.G.M.¹, Vissink A.¹, Valstar M.²
¹Groningen, The Netherlands, ²Amsterdam, The Netherlands

PO1:21 DOES ANCESTRY INFLUENCE PRIMARY SJÖGREN'S SYNDROME PHENOTYPE OR SEVERITY?

Beydon M.*¹, Seror R.¹, Desmoulins F.¹, Mariette X.², Nocturne G.¹
¹Paris, France, ²Le Kremlin Bicêtre, France

PO1:22 CCR9/CXCR5 CO-EXPRESSING CD4 T CELLS ARE INCREASED IN PRIMARY SJÖGREN'S SYNDROME AND ENRICHED IN PD-1/ICOS EXPRESSING EFFECTOR T CELLS

Hinrichs A., Leavis H., Kruize A., Lafeber F., Van Roon J.*
Utrecht, The Netherlands

PO1:23 IL-1 ALPHA AND IL-1 BETA EXPRESSION IN PRIMARY SJÖGREN'S SYNDROME SALIVARY GLAND EPITHELIAL CELLS

Izzo R.*¹, Colafrancesco S., Barbati C., Buoncuore G., Gattamelata A., Giardina F., Simoncelli, E., Mastromanno L., Villa M., Conti F., Priori R.
¹Rome, Italy

PO1:24 IDENTIFYING POTENTIAL PATHOGENIC MECHANISMS IN PRIMARY SJÖGREN'S SYNDROME USING METABOLOMICS AND MACHINE LEARNING APPROACHES

Martin-Gutierrez L.*¹, Zhang S., Peng J., Robinson G., Butt M., Ciurtin C., Jury E.
London, UK



POSTER

PO1:26 MITOCHONDRIAL DYSFUNCTION IN SJÖGREN'S SYNDROME

Kurien B.T.*¹, Pharaoh G., Cavett J., Lewis V., Chambers A., Bhaskaran S., Anjum J., Karfonta B., Radfar L., Rasmussen A., Lessard C.J., Farris A.D., Sivils K., Koelsch K.A., Van Remmen H., Scofield R.H.
Oklahoma City, USA

PO1:27 INVOLVEMENT OF INTERFERON IN THE PATHOPHYSIOLOGY OF VAGINAL DRYNESS IN PRIMARY SJÖGREN'S SYNDROME.

Visser A.*¹, Nimwegen J., Bootsma H., Van Der Tuuk K., Mourits M., Van Kempen L., Kroese F.G.M., Verstappen G.
Groningen, The Netherlands

PO1:28 DEEP SPATIAL PROFILING OF SJÖGREN SYNDROME PATIENTS BY IMAGING MASS CYTOMETRY: PRELIMINARY RESULTS

Chatzis L.*¹, Hemon P.², Scuiller Y.², Goules A.V.¹, Tzioufas A.G.¹, Pers J.O.²
¹ Athens, Greece, ² Brest, France

PO1:30 TLR7 REGULATES X-LINKED TLR ADAPTOR ENDOLYSOSOMAL SLC15A4 (TASL) EXPRESSION IN SJÖGREN'S DISEASE SUBJECTS

Harris-Lewis V.*¹, Bruxvoort C., Lawrence S., Cavett J., Kurien B., Scofield R.H.
Oklahoma City, USA

PO1:31 REGULATION OF STAT4 EXPRESSION BY GROWTH FACTOR SUPPLEMENTATION IN SJÖGREN'S SYNDROME CELL CULTURE MODELS

Mougeot J.*¹, Noll B.², Thornburg T., Noll J., Cathleen P., Lizano M., Brennan M., Mougeot F.
Charlotte, USA

PO1:32 AUTOPHAGY-RELATED PRDM1-ATG5 RISK LOCUS IN SJÖGREN'S DISEASE

Nagel A.¹, Khatri B.¹, Radziszewski M.¹, Wiley M.¹, Stolarczyk A.¹, Joachims M.¹, Tessneer K.¹, Rasmussen A.¹, Bowman S.J.², Radfar L.¹, Omdal R.³, Wahren-Herlenius M.⁴, Warner B.⁵, Witte T.⁶, Jonsson R.⁷, Rischmueller M.⁸, Gaffney P.¹, James J.A.¹, Rönnblom L.⁹, Scofield R.H.¹, Mariette X.¹⁰, Alarcón-Riquelme M.E.¹¹, Ng W.F.¹², Nordmark G.⁹, Farris A.D.¹, Lessard C.J.*¹
¹ Oklahoma City, USA, ² Birmingham, UK, ³ Stavanger, Norway, ⁴ Stavanger, Norway, ⁵ Bethesda, USA, ⁶ Hannover, Germany, ⁷ Bergen, Norway, ⁸ Adelaide, Australia, ⁹ Uppsala, Sweden, ¹⁰ Le Kremlin Bicêtre, France, ¹¹ Granada, Spain, ¹² Newcastle Upon Tyne, UK

PO1:34 ELEVATED LEVELS OF IL-9 FAIL TO SUPPRESS PATHOGENIC TH17 CELLS IN SJÖGREN'S SYNDROME

Voigt A.*¹, Shen Y., Nguyen C.
Gainesville, USA

POSTER

P01:35 UNIQUE BIOLOGICAL PROFILE OF GERMINAL CENTRES WITHIN TERTIARY LYMPHOID STRUCTURES IN THE SALIVARY GLANDS OF PATIENTS WITH SJÖGREN'S SYNDROME

Nayar S.*¹, Turner J.D.¹, Asam S.¹, Colfrancesco S.², Berardicurti O.³, Iannizzotto V.¹, Smith C.¹, Flint J.¹, Teodósio A.¹, Gardner D.H.¹, Bowman S.J.¹, Ng W.F.⁴, Croft A.P.¹, Filer A.¹, Fisher B.A.¹, Buckley C.D.⁵, Barone F.⁶

¹Birmingham, UK, ²Rome, Italy, ³L'Aquila, Italy, ⁴Newcastle upon Tyne, UK, ⁵Oxford, UK, ⁶Massachusetts, USA

P01:36 ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) AUTOANTIBODIES AS POTENTIAL BIOMARKER OF FATIGUE IN PATIENTS WITH SJÖGREN SYNDROME

Marinoska T.*¹, Möckel T.², Dreher M.², Schwarting A.²

¹Bad Kreuznach, Germany, ²Mainz, Germany

P01:37 ONSET OF PAROTID SWELLING AND SUBSEQUENT PRIMARY SJÖGREN'S SYNDROME AFTER RUBELLA VACCINE

Manfrè V.*¹, Fabro C., Longhino S., Rizzo M.T., Giovannini I., Pegolo E., Zabotti A., Quartuccio L., De Vita S.

Udine, Italy

P01:38 ANALYSIS OF IFN-REGULATED CHEMOKINES AND B CELL SUBSETS IN PEDIATRIC SJÖGREN'S SYNDROME

Boni A., Pires Marafon D., Caiello I., Matteo V., Marasco E.*¹, Prencipe G., Nicolai R., Bracaglia C., De Benedetti F.

Rome, Italy

2. EVOLVING TOPICS IN pSS STRATIFICATION

P02:39 ALTERED CELL FREQUENCIES IN PATIENTS WITH SJÖGREN'S SYNDROME

Sarkar I., Aarebrot A.K., Solberg S.M., Petrovic A., Davies R., Joshi A.M., Brith B., Brun J.G., Hammenfors D., Jonsson R., Appel S.*

Bergen, Norway

P02:40 SJÖGREN'S AND NON-SJÖGREN'S SICCA SHARE A SIMILAR SYMPTOM BURDEN BUT WITH A DISTINCT SYMPTOM-ASSOCIATED PROTEOMIC SIGNATURE

Pucino V.*¹, Jason D.T.¹, Nayar S.¹, Florian K.², Rauz S.¹, Richards A.¹, Poveda-Gallego A.¹, Higham J.¹, Bowman S.J.¹, Barone F.³, Fisher B.A.¹

¹Birmingham, UK, ²Bern, Switzerland, UK, ³Boston, USA

P02:41 SYSTEMIC INVOLVEMENT IN SJÖGREN SYNDROME: CAN WE PREDICT IT?

Bandeira M.*¹, Silvério António M., Khmelinskii N., Eurico Fonseca J., Romão V.C.

Lisbon, Portugal

P02:42 AUTOANTIBODIES AGAINST AQUAPORIN-5 IN PRIMARY SJÖGREN SYNDROME AS POTENTIAL DISEASE ACTIVITY AND PROGNOSTIC BIOMARKER.

Stano S.*

Bari, Italy



POSTER

PO2:43 ANTI-SSA/RO PROFILING IN PATIENTS WITH NEWLY DIAGNOSIS OF SJÖGREN SYNDROME: IMPACT ON "SICCA" AND "NON-SICCA" DISEASE ONSET

Fonzetti S.*¹, Ferro F., Fulvio G., La Rocca G., Navarro Garcia I.C., Donati V., Mosca M., Baldini C.
Pisa, Italy

PO2:44 SJÖGREN'S SYNDROME ILD PREVALENCE AND ASSOCIATED RISK FACTORS, A MONOCENTRIC COHORT STUDY

La Rocca G.*¹, Ferro F., Fulvio G., Fonzetti S., Navarro I., Elefante E., Mosca M., Baldini C.
Pisa, Italy

PO2:45 COMPREHENSIVE ANALYSIS OF CLINICAL AND LABORATORY FEATURES OF 440 PUBLISHED CASES OF PRIMARY SJÖGREN'S SYNDROME AND RENAL TUBULAR ACIDOSIS

Sandhya P.*¹
Delhi, India

PO2:46 JUVENILE PRIMARY SJÖGREN SYNDROME – CLINICAL INSIGHTS

Rajão Martins F.*¹, Aguiar F.², Rodrigues M.², Brito I.²
¹*Faro, Portugal*, ²*Porto, Portugal*

PO2:47 CHARACTERIZATION OF SEROPOSITIVE AND SERONEGATIVE SJÖGREN'S SYNDROME ACCORDING TO THE 2016 ACR/EULAR CLASSIFICATION CRITERIA

Longhino S.*¹, Manfrè V., Rizzo M.T., De Vita S., Quartuccio L.
Udine, Italy

PO2:48 WHAT DOES ISOLATED ANTI-RO52 ANTIBODY POSITIVITY MEAN IN SJÖGREN'S SYNDROME?

Bettacchioli E.*¹, Saraux A.¹, Tison A.¹, Cornec D.¹, Dueymes M.¹, Alarcón-Riquelme M.E.², Devauchelle-Pensec V.¹

¹*Brest, France*, ²*Granada, Spain*

PO2:49 PALPABLE PURPURA ASSOCIATED RISK FACTORS IN PRIMARY SJÖGREN'S SYNDROME BY DATA DRIVEN ANALYSIS IN HARMONIZED PATIENTS.

Goules A.V.*¹, Pezoulas V.C.², Kalatzis F.², Chatzis L.¹, Kourou D.K.², Venetsanopoulou A.², Exarchos T.P.², Gandolfo S.³, Votis K.⁴, Zampeli E.¹, Burmeister J.⁵, May T.⁵, Perez M.M.⁶, Lishchuk I.⁷, Chondrogiannis E.¹, Karanastasis E.¹, Andronikou V.¹, Varvarigou T.¹, Filipovic N.⁸, Tsiknakis M.⁹, Baldini C.¹⁰, Bombardieri M.¹¹, Bootsma H.¹², Bowman S.J.¹³, Shahnawaz Soyfoo M.¹⁴, Parisi D.¹⁴, Delporte C.¹⁴, Devauchelle-Pensec V.¹⁵, Pers J.O.¹⁵, Dörner T.¹⁶, Bartoloni E.¹⁷, Gerli R.¹⁷, Giacomelli R.¹⁸, Jonsson R.¹⁹, Ng W.F.²⁰, Colafrancesco S.²¹, Priori R.²¹, Ramos-Casals M.²², Mavragani P.C.¹, Sivils K.²³, Skopouli F.¹, Torsten W.⁷, Van Roon J.²⁴, Xavier M.²⁵, De Vita S.³, Moutsopoulos H.M.¹, Fotiadis D.I.², Tzioufas A.G.¹

¹ *Athens, Greece*, ² *Ioannina, Greece*, ³ *Udine, Italy*, ⁴ *Thessaloniki, Greece*, ⁵ *Darmstadt, Germany*, ⁶ *Madrid, Spain*, ⁷ *Hannover, Germany*, ⁸ *Kragujevac, Greece*, ⁹ *Heraklion, Greece*, ¹⁰ *Pisa, Italy*, ¹¹ *London, UK*, ¹² *Groningen, The Netherlands*, ¹³ *Birmingham, UK*, ¹⁴ *Brussels Belgium*, ¹⁵ *Brest, France*, ¹⁶ *Berlin, Germany*, ¹⁷ *Perugia, Italy*, ¹⁸ *L'Aquila, Italy*, ¹⁹ *Bergen, Norway*, ²⁰ *Newcastle upon Tyne, UK*, ²¹ *Rome, Italy*, ²² *Barcelona, Spain*, ²³ *Oklahoma, USA*, ²⁴ *Utrecht, The Netherlands*, ²⁵ *Paris, France*

POSTER

PO2:51 COLOR DOPPLER ASSESSMENT OF SALIVARY GLANDS IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME

Giovannini I.*¹, Manfrè V.¹, Hocevar A.², Quartuccio L.¹, De Vita S.¹, Zabotti A.¹
¹Udine, Italy, ²Ljubljana, Slovenia

PO2:52 TOP LINE RESULTS FROM NOPRODNAP0017: A DIRECT-TO-PATIENT LONGITUDINAL STUDY FOR DIGITAL AND BIOMARKER DISEASE PROFILING OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND SJÖGREN'S SYNDROME (PSS)

Avey S.*¹, Reynoso E.¹, Hu X.¹, Ven K.², Pandis I.³, Bonet D.¹, Lontoc T.¹, Patel C.¹, Mosca K.¹, Liu G.¹, Morris M.¹, Murphy P.³, Franks C.¹, Leszczuk J.¹
¹Spring House, USA, ²Beerse, Belgium, ³London, UK

PO2:53 DIAGNOSTIC VALUE OF MONOSPECIFIC ANTI-DFS70 ANTIBODIES IN PRIMARY SJÖGREN'S SYNDROME

Khvan Y.*¹, Torgashina A., Chaltsev B., Verizhnikova Z.
Moscow, Russian Federation

3. EVOLVING TOPICS IN pSS - RELATED LYMPHOPROLIFERATION

PO3:54 EARLY DETECTION OF MALT LYMPHOMA IN SJÖGREN'S SYNDROME PATIENTS THROUGH IMMUNOGENETICS

Kolijn P.M.*¹, Huijser E., Wahadat M.J., Van Helden-Meeuwse C.G., Van Daele P.L., Versnel M.A., Langerak A.W.
Rotterdam, The Netherlands

PO3:55 CHARACTERISTICS, PREDICTIVE AND PROGNOSIS FACTORS OF RELAPSE OR DEATH FOR NON-HODGKIN LYMPHOMAS IN PRIMARY SJÖGREN SYNDROME

Rocca J.¹, Beydon M.¹, Le Guern V.², Hachulla E.³, Dubost J.J.⁴, Jousse-Joulin S.⁵, Devauchelle-Pensec V.⁵, Gottenberg J.E.⁶, Vittecoq O.⁷, Lavigne C.⁸, Schmidt J.⁹, Marcelli C.¹⁰, Larroche C.¹¹, Mariette X.¹, Nocturne G.^{1*}, Seror R.¹
¹Le Kremlin Bicêtre, France, ²Paris, France, ³Lille, France, ⁴Clermont Ferrand, France, ⁵Brest, France, ⁶Strasbourg, France, ⁷Rouen, France, ⁸Angers, France, ⁹Amiens, France, ¹⁰Caen, Finland, ¹¹Bobigny, France

PO3:56 HIGHER LYMPHOMA RISK IN SJÖGREN'S SYNDROME IN THE NORTH EAST OF ITALY OVER 15 YEARS OF FOLLOW-UP: THE FIRST ITALIAN STUDY MATCHING THE CANCER REGISTRY AND THE ADMINISTRATIVE DATABASE

Treppo E.*¹, Toffolutti F.², Manfrè V.¹, Taborelli M.², De Vita S.¹, Serraino D.², Quartuccio L.¹
¹Udine, Italy, ²Aviano, Italy

PO3:57 THE COURSE OF PRIMARY SJÖGREN'S SYNDROME PRIOR TO THE DEVELOPMENT OF LYMPHOMA: SHOULD SYSTEMIC THERAPY BE USED IN THE TREATMENT OF GLANDULAR FORMS OF THE DISEASE?

Chaltsev B., Vasiliev V., Torgashina A., Khvan Y., Sokol E.*
Moscow, Russian Federation



POSTER

P03:58 MARGINAL ZONE LYMPHOMAS IN PRIMARY AND SECONDARY SJÖGREN'S SYNDROME

Vasiliev V., Palshina S., Gaiduk I., Probatova N., Gorodetskiy V., Kokosadze N., Shornikova N., Rodionova E., Safonova T., Aleksandrova E., Chaltsev B., Torgashina A., Sokol E.* , Novikov A.
Moscow, Russian Federation

P03:60 SALIVARY GLAND ULTRASONOGRAPHY IN MALT LYMPHOMA COMPLICATING SJÖGREN'S SYNDROME: DYNAMIC CHANGES AFTER IMMUNOSUPPRESSIVE TREATMENT

Torgashina A.* , Chaltsev B., Khvan Y.
Moscow, Russian Federation

P03:61 UNCERTAIN DIAGNOSIS OF MALT LYMPHOMA IN SJÖGREN'S SYNDROME: THE POSSIBLE ROLE OF CENTROCYTE-LIKE CELL CONFLUENCE AND B-CELL CLONALITY FOR A BETTER STRATIFICATION

Longhino S.* , Scott C.A., Fabro C., Quartuccio L., De Vita S.
Udine, Italy

P03:62 LYMPHADENOPATHY IN SJÖGREN SYNDROME

Chatzis L.*¹, Pezoulas V.C.², Stergiou I.¹, Paraskevi V.², Baldini C.³, Exarchos T.P.², Fotiadis D.I.², Skopouli F.¹, Goules A.V.¹, Voulgarelis M.¹, Moutsopoulos H.M.¹, Tzioufas A.G.¹
¹ Athens, Greece, ²Ioannina, Greece, ³Pisa, Italy

P03:63 EXPRESSION OF MIR-155 IN SALIVARY GLANDS TISSUE OF PRIMARY SJÖGREN'S SYNDROME: CORRELATION WITH DISEASE CHARACTERISTICS AND LYMPHOPROLIFERATIVE EVOLUTION

Bruno D.* , Di Mario C., Paglionico A., Varriano V., Ferraccioli G., Tulusso B., Alivernini S., Gremese E.
Rome, Italy

P03:64 PREDICTING LYMPHOMA IN PRIMARY SJÖGREN'S SYNDROME: THE ROLE OF PRECISE PAROTID SWELLING RECORDING

Rizzo M.T.*¹, Isola M.¹, Baldini C.², Goules A.V.³, Chatzis L.³, Quartuccio L.¹, Zabotti A.¹, Giovannini I.¹, Donati V.², Ferro F.², Pegolo E.¹, Manfrè V.¹, Voulgarelis M.³, Zaja F.⁴, Fanin R.¹, Masaoutis C.³, Rontogianni D.³, Fotiadis D.I.⁵, Ponzoni M.⁶, Tzioufas A.G.⁴, De Vita S.¹
¹ Udine, Italy ²Pisa, Italy, ³ Athens, Greece ⁴Trieste, Italy, ⁵ Ioannina, Greece, ⁶Milan, Italy

P03:66 EFFICACY OF RITUXIMAB ON CLINICAL, HISTOLOGICAL, IMMUNOHISTOCHEMICAL AND MOLECULAR CHARACTERISTICS OF MALT-LYMPHOMA IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME.

Chaltsev B.* , Torgashina A., Khvan Y.
Moscow, Russian Federation

POSTER

4. EVOLVING TOPICS IN THE EVALUATION OF pSS

PO4:67 HOW TO EVALUATE ULTRASOUND ABNORMALITIES OF SALIVARY GLANDS IN SJÖGREN SYNDROME USING WEB TRAINING SESSION DURING COVID 19 PERIOD? AN INTERNATIONAL RELIABILITY EXERCISE

Quére B.*¹, Saraux A.¹, Carvajal Alegria G.², Guellec D.¹, Mouterde G.³, Lamotte C.⁴, Hammenfors D.⁵, Jonsson M.⁵, Sung-Eun C.⁶, Hong-Ki M.⁷, Stel A.⁸, Fisher B.A.⁹, Hofauer B.¹⁰, Ferro F.¹², Milic V.¹¹, Dizenzo D.¹³, Devauchelle-Pensec V.¹, Jousse-Joulin S.¹

¹Brest, France, ²Tours, France, ³Montpellier, France, ⁴Lille, France, ⁵Bergen, Norway, ⁶Gwangju, Korea, Republic of Korea, ⁷Seoul, Korea, Republic of Korea, ⁸Groningen, The Netherlands, ⁹Birmingham, UK, ¹⁰Freiburg, Germany, ¹¹Belgrade, Serbia, ¹²Pisa, Italy, ¹³Philadelphia, USA

PO4:68 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME IN DAILY CLINICAL PRACTICE

De Wolff L.*¹, Vissink A., Mossel E., Van Zuiden G., Van Nimwegen J., Olie L., Stel A., Delli K., Verstappen G., Kroese F.G.M., Bootsma H., Arends S.

Groningen, The Netherlands

PO4:69 ASSOCIATION BETWEEN SALIVARY SCINTIGRAPHIC AND HISTOPATHOLOGIC DATA OF MINOR SALIVARY GLANDS IN PRIMARY SJÖGREN'S SYNDROME

Han J.H.*¹, Kim J., Roh J., Kim H.

Suwon, Korea, Republic of Korea

PO4:70 COMPARISON BETWEEN PRIMARY SJÖGREN'S SYNDROME PATIENTS WITH AND WITHOUT DRYNESS

Kachaner A.*¹, Mariette X.², Desmoulins F.², Nocturne G.², Seror R.²

¹Paris, France, ²Kremlin Bicêtre, France

PO4:71 THE COURSE OF JUVENILE ONSET SJÖGREN'S SYNDROME

Vasiliev V., Palshina S., Shornikova L.*¹, Rodionova E., Novikov A.

Moscow, Russian Federation

PO4:72 AUTOMATIC QUANTIFICATION OF DRY EYE BY ARTIFICIAL INTELLIGENCE IN THE CONTEXT OF SJÖGREN'S SYNDROME

Brahim I.*¹, Lamard M., Ben-Youssef A., Conze P., Cochner-Lamard B., Quellec G., Cornec D.

Brest, France

PO4:73 SALIVARY GLAND ULTRASONOGRAPHY (SGUS) IN PRIMARY SJÖGREN'S SYNDROME AS MARKER OF DISEASE SEVERITY AND ITS ASSOCIATIONS WITH CLINICAL CHARACTERISTICS, ESSDAI AND ESSPRI AND SALIVARY PROTEOMICS.

Bisaralli R., Rath P.D., Nanda R., Sahu A.K., Chouhan S.

New Delhi, India

PO4:74 AUTONOMIC DYSFUNCTION IN SJÖGREN'S DISEASE

Fenando A.¹, Estes J.¹, Shah S.¹, Lee J.¹, Jabari D.¹, Baker J.², Noaiseh G.*¹

¹Kansas City, USA, ²Philadelphia, USA



POSTER

PO4:75 DRY EYE SYMPTOMS STRONGLY CORRELATE WITH OCULAR AND EXTRAOCULAR PAIN IN PRIMARY SJÖGREN'S SYNDROME. INTERIM REPORT OF A PILOT CROSS-SECTIONAL MONOCENTRIC STUDY.

Moroni L., Ferrari G., Bonelli F., Batani V.* , Bellone M., Dagna L.
Milan, Italy

PO4:76 ECOLOGICAL MOMENTARY ASSESSMENT OF THE SYMPTOMS IN SJÖGREN'S SYNDROME: DEVELOPMENT AND VALIDATION OF A DEDICATED WEBAPP

Georgel L.¹, Berrouguet S.¹, Ben-Youssef A.¹, Guellec D.¹, Carvajal Alegria G.², Marhadour T.¹, Jousse-Joulin S.¹, Cochener B.¹, Labetoulle M.³, Saraux A.¹, Gravey M.¹, Devauchelle-Pensec V.¹, Seror R.³, Cornec D.*¹
¹Brest, France, ²Tours, France, ³Kremlin-Bicêtre, France

PO4:77 IN-DEPTH ANALYSIS OF SALIVARY GLAND BIOPSIES: DEVELOPMENT OF NEW TOOLS USING HYPERION MASS CYTOMETRY TO ACCURATELY DETERMINE SJÖGREN'S SEVERITY STATUS

Scuiller Y.* , Foulquier N., Hemon P., Pers J.O., Jamin C.
Brest, France

PO4:78 INFLUENCE OF EPIDEMIOLOGY AND ETHNICITY ON SYSTEMIC EXPRESSION OF PRIMARY SJÖGREN SYNDROME AT DIAGNOSIS: WORLDWIDE PATTERNS IN 14,836 PATIENTS (2022 SJÖGREN BIG DATA PROJECT)

Retamozo S.*¹, Szántó A.², Li X.³, Rasmussen A.⁴, Ng W.F.⁵, Dong X.⁶, Priori R.⁷, Olsson P.⁸, Baldini C.⁹, Seror R.¹⁰, Bootsma H.¹¹, Armagan B.¹², Gottenberg J.E.¹⁴, Kruize A.¹⁵, Hernandez-Molina G.¹³, Paprovnik S.¹⁶, Danda D.¹⁷, Özkiziltas B.¹⁸, Inanc N.¹⁹, Quartuccio L.²⁰, Sebastian A.²¹, Gerli R.²², Romão V.C.²³, Rischmueller M.²⁴, Suzuki Y.²⁵, Kwok S.²⁶, Kvarnstrom M.²⁷, Solans R.²⁸, Pasoto S.G.²⁹, Galisteo C.³⁰, Sene D.³¹, Moça Trevisani V.³², Isenberg D.³³, Hofauer B.³⁴, Shimizu T.³⁵, Nordmark G.³⁶, Valim V.³⁷, Jurcut C.³⁸, Carubbi F.³⁹, González García A.⁴⁰, Devauchelle-Pensec D.⁴¹, Melchor Díaz S.⁴², Gheita T.A.⁴³, Brito-Zerón P.⁴⁴, López-Dupla M.⁴⁵, Fonseca-Aizpuru E.⁴⁶, Sánchez-Berná I.⁴⁷, Morel J.⁴⁸, Giacomelli R.⁴⁹, Atzeni F.⁵⁰, Consani C.⁵¹, Vázquez M.⁵², Akasbi M.⁵³, Flores-Chavez A.⁵⁴, Ramos-Casals M.⁵⁴
¹Barcelona, Spain, ²Debrecen, Hungary, ³Hefei, Anhui, China, ⁴Oklahoma, USA, ⁵Newcastle upon Tyne, UK, ⁶Beijing, China, ⁷Rome, Italy, ⁸Malmö, Sweden, ⁹Pisa, Italy, ¹⁰Paris, France, ¹¹Groningen, The Netherlands, ¹²Ankara, Turkey, ¹³Ciudad de Mexico, Mexico, ¹⁴Strasbourg, France, ¹⁵Utrecht, The Netherlands, ¹⁶Ljubljana, Slovenia, ¹⁷Tamil Nadu, India, ¹⁸Ankara, Turkey, ¹⁹Istanbul, Turkey, ²⁰Udine, Italy, ²¹Wroclaw, Poland, ²²Perugia, Italy, ²³Lisboa, Portugal, ²⁴Adelaide, Australia, ²⁵Kanazawa, Japan, ²⁶Seoul, Korea, Republic of Korea, ²⁷Stockholm, Sweden, ²⁸Barcelona, Spain, ²⁹São Paulo, Brazil, ³⁰Paris, France, ³²São Paulo, Brazil, ³³London, UK, ³⁴Munich, Germany, ³⁵Nagasaki, Japan, ³⁶Uppsala, Sweden, ³⁷Vitoria, Espiritu Santo, Brazil, ³⁸Bucharest, Romania, ³⁹L'Aquila, Italy, ⁴⁰Madrid, Spain, ⁴¹Brest, France, ⁴²Madrid, Spain, ⁴³Cairo, Egypt, ⁴⁴Barcelona, Spain, ⁴⁵Tarragona, Spain, ⁴⁶Asturias, Spain, ⁴⁷Madrid, Spain, ⁴⁸Montpellier, France, ⁴⁹Rome, Italy, ⁵⁰Milan, Italy, ⁵¹Montevideo, Uruguay, ⁵²San Lorenzo, Paraguay, ⁵³Madrid, Spain, ⁵⁴Barcelona, Spain

POSTER

PO4:79 ESSPRI REFLECTS COMMON SYMPTOMS OF PRIMARY SJÖGREN'S SYNDROME BETTER THAN ESSDAI

Ilgen U.*¹, Erol Kalkan K.², Ademoglu Z.³, Hakan E.³
¹Bitlis, Turkey, ²Istanbul, Turkey, ³Edirne, Turkey

PO4:81 SERUM BETA2-MICROGLOBULIN AS A MARKER OF ACTIVE PRIMARY SJÖGREN'S SYNDROME AND EXTRAGLANDULAR INVOLVEMENT

Bueno I.B.*¹, Oliveira M.C., Oliveira F.R.
Ribeirão Preto, Brazil

PO4:82 ULTRASONOGRAPHY OF LACRIMAL GLANDS: UNDERESTIMATE TOOL IN PRIMARY SJÖGREN'S SYNDROME. A CASE REPORT

Giovannini I.¹, Zandonella Callegher S.², Longhino S.*¹, Manfrè V.¹, De Vita S.¹, Zabotti A.¹
¹Udine, Italy, ²Brunico, Italy

PO4:83 VALIDITY OF THE NOVEL OMERACT ULTRASOUND SCORING SYSTEM FOR SALIVARY GLANDS TARGET LESIONS IN SJÖGREN'S SYNDROME

Inanc N.*¹, Jousse-Joulin S.², Abacar K.¹, Cimsit Ç.¹, Cimsit C.¹, D'Agostino M.³, Naredo E.⁴, Hocevar A.⁵, Finzel S.⁶, Terslev L.⁷, Pineda C.⁸, Keen H.⁹, Iagnocco A.¹⁰, Hanova P.¹¹, Schmidt W.A.¹², Mumcu G.¹, Bruyn G.A.W.¹³
¹Istanbul, Turkey, ²Brest, France, ³Versailles, France, ⁴Madrid, Spain, ⁵Ljubljana, Slovenia, ⁶Freiburg, Germany, ⁷Copenhagen, Denmark, ⁸Ciudad de México, Mexico, ⁹Perth, Australia, ¹⁰Turin, Italy, ¹¹Prague, Czech Republic, ¹²Berlin, Germany, ¹³Lelystad, The Netherlands

PO4:84 ULTRASOUND EVALUATION OF MAJOR SALIVARY GLANDS IN AN ITALIAN COHORT OF PRIMARY SJÖGREN'S SYNDROME PATIENTS: A MONOCENTRIC STUDY

Giardina F.*¹, Gattamelata A., Colafrancesco S., Mastromanno L., Villa M., Simoncelli E., Izzo R., Conti F., Priori R.
Rome, Italy

PO4:86 COMPREHENSIVE ASSESSMENT OF PATIENTS WITH SUSPECTED SJÖGREN'S SYNDROME: 5-YEAR RESULTS OF A MULTIDISCIPLINARY SJÖGREN'S SYNDROME CLINIC

Romão V.C.*¹, Bandeira M., Silvério António M., Simão R., Pinto J., Gonçalves A.I., Gonçalves M.J., Martins A.L., Lopes P., Morena Bueno Silva L., Lança M., Coutinho G., Esteves Marques R., Macieira C., Khmelinskii N., Rodrigues W., Salvado F., Fonseca J.E.
Lisbon, Portugal

PO4:87 NOVEL AUTOANTIBODIES IDENTIFY SJÖGREN'S DISEASE IN PATIENTS LACKING SERUM IGG SPECIFIC FOR RO/SS-A AND LA/SS-B

Longobardi S., Lopez-Davis C., Khatri B., Georgescu C., Lawrence C., Rasmussen A., Radfar L., Scofield R.H., Axtell R.C., Pardo G., Wren J.D., Koelsch K.A., Guthridge J., James J.A., Lessard C.J., Farris A.D.*
Oklahoma City, USA



POSTER

PO4:88 DOES EULAR SJÖGREN'S SYNDROME PATIENT REPORTED INDEX (ESSPRI)-PAIN MODERATE DAILY ACTIVITY IMPAIRMENT IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME?

Yenisoy Y.¹, Altıngöz E.N.¹, Kapusuz A.¹, Abacı K.Y.¹, Tatlı I.¹, Türe-Özdemir F.¹, Karacaylı U.², Yay M.¹, Direskeneli H.¹, Fortune F.³, İnanc N.*¹, Mumcu G.¹

¹Istanbul, Turkey, ²Ankara, Turkey, ³London, UK

PO4:89 POSTURAL TACHYCARDIA AND SJÖGREN DISEASE

Goodman B.* , Arca K.

Scottsdale, USA

PO4:90 THE SJÖGREN'S TOOL FOR ASSESSING RESPONSE (STAR): ASSESSMENT OF RESPONSE RATES OVERALL, ACCORDING TO BAŞELINE ACTIVITY AND BY DOMAIN: REANALYSIS OF 9 CLINICAL TRIALS IN PRIMARY SJÖGREN'S SYNDROME

Seror R.*¹, Baron G.¹, Cornec D.², Perrodeau E.¹, Camus M.¹, Bowman S.J.³, Bombardieri M.⁴, Bootsma H.⁵, Arends S.⁵, Gottenberg J.E.⁶, Fisher B.A.⁷, Hueber W.⁸, Roon J.V.⁹, Devauchelle-Pensec V.², De Wolff L.⁶, Gergely P.⁸, Mariette X.¹, Porcher R.¹

¹Paris, France, ²Brest, France, ³Milton Keynes, UK, ⁴London, UK, ⁵Groningen, The Netherlands, ⁶Strasbourg, France, ⁷Birmingham, UK, ⁸Basel, Switzerland, ⁹Utrecht, The Netherlands

PO4:91 COMPARISON OF ULTRASOUND AND SIALOGRAPHY OF MAJOR SALIVARY GLANDS IN PRIMARY SJÖGREN'S SYNDROME

Khvan Y.* , Torgashina A., Chaltsev B.

Moscow, Russian Federation

PO4:92 ULTRASOUND OF SALIVARY GLANDS IN PATIENTS WITH POSITIVE AND NEGATIVE ANTICENTROMERE ANTIBODIES PRIMARY SJÖGREN'S SYNDROME

Khvan Y., Torgashina A., Chaltsev B.*

Moscow, Russian Federation

PO4:94 CASE SERIES OF EXTRAGLANDULAR MANIFESTATIONS OF PRIMARY SJÖGREN SYNDROME IN A UNIVERSITY HOSPITAL OF BOGOTÁ, COLOMBIA.

Borda Samper C.* , Navarrete Motta L.E., Bernal Macías S., Fernández Ávila D.G., Díaz M.C., Gutierrez Davila J.M., González Rojas B.J.

Bogotá, Colombia

POSTER

5. ASSOCIATION OF SS WITH OTHER DISEASES: IMPLICATIONS IN DISEASE BIOLOGY AND MANAGEMENT

PO5:95 SEX HORMONES AND RELATED COMORBIDITIES ARE ASSOCIATED WITH DEVELOPING SJÖGREN'S DISEASE: A POPULATION-BASED NESTED CASE-CONTROL STUDY

Mccoy S.*¹, Hetzel S.¹, Vanwormer J.², Bartels C.¹
¹Madison, USA, ² Marshfield, USA

PO5:97 MALIGNANCIES AMONG PATIENTS WITH SJÖGREN'S SYNDROME

Szántó A.*¹, Aradi Z., Orosz V.
Debrecen, Hungary

PO5:98 SALIVARY GLANDS ULTRASONOGRAPHY VALUE IN RHEUMATOID ARTHRITIS PATIENTS WITH DRY SYNDROME

Rabault R.*¹, Jousse-Joulin S., Saraux A., Courtois-Communier E., Cornec D., Guellec D., Marhadour T., Houssais C., Tison A., Devauchelle-Pensec V.
Brest, France

PO5:99 SIGNIFICANCE OF RHEUMATOID FACTOR ISOTYPES IN PATIENTS WITH SJÖGREN'S SYNDROME WITH JOINT COMPLAINTS OF DIFFERENT ETIOLOGY

Aradi Z.*¹, Nagy G., Szántó A.
Debrecen, Hungary

PO5:100 MYOSITIS IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME: DATA FROM A FRENCH NATION-WIDE SURVEY

Houssais C.¹, Noury J.¹, Allenbach Y.², Gallay L.³, Quéré B.*¹, Assan F.⁴, Benveniste O.², Broner J.⁵, Duffau P.⁶, Espitia A.⁷, Grasland A.⁸, Sanges S.⁹, Hachulla E.⁹, Hayem G.⁴, Le Guern V.¹⁰, Martis N.¹¹, Mariampillai K.², Mulleman D.¹², Nocturne G.¹³, Mariette X.¹³, Meyer A.¹⁴, Devauchelle-Pensec V.¹, Cornec D.¹, Guellec D.¹
¹Brest, France, ²Paris, France, ³Lyon, France, ⁴Boulogne-Billancourt, France, ⁵Nimes, France, ⁶Bordeaux, France, ⁷Nantes, France, ⁸Colombes, France, ⁹Lille, France, ¹⁰Paris, France, ¹¹Nice, France, ¹²Tours, France, ¹³Kremlin-Bicêtre, France, ¹⁴Strasbourg, France

PO5:101 PRIMARY SJÖGREN'S SYNDROME PRESENTING AS THROMBOTIC THROMBOCYTOPENIC PURPURA IN A MALE PATIENT WITH PREVIOUS KIKUCHI-FUJIMOTO DISEASE

Silvério António M., Alves Ribeiro L., Medeiros J., Romão V.C.*¹, Fonseca J.E.
Lisbon, Portugal

PO5:102 CHARACTERIZATION OF THE ASSOCIATION BETWEEN PRIMARY SJÖGREN'S SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS (PSS/SLE)

De Marchi G.¹, Chiara B.², Elefante E.², Manfrè V.¹, Navarro I.², Giovannini I.¹, Treppo E.¹, Zabotti A.¹, Quartuccio L.^{1*}, De Vita S.¹, Longhino S.¹
¹Udine, Italy, ²Pisa, Italy



POSTER

PO5:103 CLINICAL AND HISTOLOGICAL FEATURES OF PATIENTS WITH PRIMARY SJÖGREN SYNDROME AND AUTOIMMUNE THYROIDITIS: A NATIONAL MULTICENTRIC CROSS-SECTIONAL STUDY

Celia A.I.*¹, Colafrancesco S.¹, Villa M.¹, Gattamelata A.¹, Izzo R.¹, Giardina F.¹, Simoncelli E.¹, Mastromanno L.¹, Baldini C.², Bartoloni E.³, Carubbi F.⁴, Quartuccio L.⁵, Orlandi M.⁶, Gerli R.³, Giacomelli R.⁷, De Vita S.⁵, Alessandri C.¹, Conti F.¹, Priori R.⁷

¹ Rome, Italy, ²Pisa, Italy, ³Perugia, Italy, ⁴L'Aquila, Italy, ⁵Udine, Italy, ⁶Florence, Italy, ⁷ Rome, Italy

PO5:104 IMMUNOPATHOLOGICAL SCENARIOS DEFINING COEXISTENCE BETWEEN SJÖGREN SYNDROME AND SARCOIDOSIS

Flores-Chavez A.*¹, Ng W.F.², Alunno A.⁴, Inanc N.³, Abacar K.³, Feijoo-Masso C.⁵, Seror R.⁶, Hernandez-Molina G.¹⁴, Hofauer B.⁸, Pasoto S.G.⁹, Robles A.¹⁰, Akasbi M.¹⁰, Brito-Zerón P.¹¹, López-Dupla M.¹², Retamozo S.¹¹, Bandeira M.¹³, Romão V.C.¹³, Devauchelle-Pensec V.⁷, Carubbi F.⁴, Mariette X.⁶, Ramos-Casals M.¹¹

¹Barcelona, Spain, ²UK, ³Istanbul, Turkey, ⁴Avezzano-Sulmona-L'Aquila, Italy, ⁵Sabadell, Spain, ⁶Paris, France, ⁷Brest, France, ⁸Germany, ⁹São Paulo, Brazil, ¹⁰Madrid, Spain, ¹¹Barcelona, Spain, ¹²Tarragona, Spain, ¹³Lisboa, Portugal, ¹⁴Ciudad de Mexico, Mexico

PO5:105 HIGH PREVALENCE OF SJÖGREN'S SYNDROME AMONG PRIMARY IMMUNODEFICIENCIES: A STUDY IN A TERTIARY CENTER OF NORTH-EASTERN ITALY

Longhino S., De Marchi G., Fabro C., Rizzo M.T.*¹, Manfrè V., Quartuccio L., De Vita S.
Udine, Italy

PO5:106 RESPIRATORY PATTERNS IN PATIENTS WITH SJÖGREN'S SYNDROME AND POSTURAL TACHYCARDIA

Arca K.*¹, Goodman B.
Scottsdale, USA

PO5:107 COMPARISON OF SALIVARY EXOSOMAL-RNA IN SJÖGREN'S, RHEUMATOID ARTHRITIS AND LUPUS

Singh M.*², Sawicki B.¹, Chakraborty S.¹, Cole J.¹, Lang S.¹, Yu S.¹, Johan S.¹, Papas A.²
¹Waltham, USA, ² Boston, USA

PO5:108 FEATURES OF JOINT MANIFESTATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN COMBINATION WITH SJÖGREN'S SYNDROME.

Torgashina A.*¹, Matianova E., Gordeev A.
Moscow, Russian Federation

PO5:109 EVALUATION OF SOME IMMUNOLOGICAL MARKERS IN RHEUMATOID ARTHRITIS IN COMBINATION WITH SJÖGREN'S DISEASE.

Torgashina A.*¹, Matianova E.
Moscow, Russian Federation

POSTER

7. INVOLVEMENT OF DIFFERENT SPECIALITIES IN THE CARE OF SS

PO7:111 DISTINGUISHING CHILDHOOD SJÖGREN'S DISEASE IN PATIENTS PRESENTING WITH SIALADENITIS TO A PEDIATRIC MULTIDISCIPLINARY OTOLARYNGOLOGY/RHEUMATOLOGY CLINIC

Holley A.*¹, Park A., Stern S.
Salt Lake City, USA

PO7:112 MULTI-SPECIALTY COLLABORATION IN DEVELOPMENT OF GUIDELINES FOR MANAGEMENT OF NEUROLOGICAL MANIFESTATIONS OF SJÖGREN'S DISEASE

Fox R.I.², Deboo A.³, Hammitt K.M.*¹, Baker M.C.⁴, Bloch D.⁶, Danielides S.⁵, De Sousa E.⁷, Goodman B.⁸, Mandel S.⁹, Noaiseh G.¹⁰, Pavlakis P.P.¹¹, Sarka G.¹², Varadhachary A.¹³, Wallace D.J.¹⁴, Makara M.¹, Scofield R.H.¹⁵, Carsons S.E.¹⁶, Carteron N.L.¹⁷
¹Reston, USA, ²La Jolla, USA, ³Philadelphia, USA, ⁴Stanford, USA, ⁵Richmond, USA, ⁶Boston, USA, ⁷Moore, USA, ⁸Phoenix, USA, ⁹Northwell, New York, USA, ¹⁰Kansas City, USA, ¹¹New York, USA, ¹²Los Angeles, USA, ¹³Saint Louis, USA, ¹⁴Beverly Hills, USA, ¹⁵Oklahoma City, USA, ¹⁶Mineola, USA, ¹⁷San Francisco, USA

PO7:113 NEW INSIGHT INTO OCULAR SURFACE DYSFUNCTION IN SJÖGREN SYNDROME.

Moawad P., Hassanein D., Shamma R., El Zawahry O., Ragab G.*
Cairo, Egypt

PO7:114 CULTURAL ADAPTATION AND PRELIMINARY VALIDATION OF THE QUALISEX QUESTIONNAIRE FOR ITS USE IN PATIENTS WITH SJÖGREN'S SYNDROME

Villa M.*¹, Giardina F.¹, Gioia C.¹, Iannuccelli C.¹, Gattamelata A.¹, Colafrancesco S.¹, Mastromanno L.¹, Simoncelli E.¹, Conti F.¹, Di Franco M.¹, Curcio G.², Priori R.¹
¹Rome, Italy, ²L'Aquila, Italy

PO7:115 HEARING DYSFUNCTION IN SJÖGREN'S SYNDROME

Simoncelli E.*¹, Gattamelata A., Giardina F., Villa M., Colafrancesco S., Mastromanno L., Izzo R., Mancini P., Portanova G., Mariani L., Atturo F., Conti F., Priori R.
Rome, Italy

PO7:116 ADHERENCE TO THE MEDITERRANEAN DIET IN ITALIAN WOMEN WITH PRIMARY SJÖGREN'S SYNDROME

Mastromanno L.*¹, Izzo R., Colafrancesco S., Barbati C., Buoncuore G., Gattamelata A., Giardina F., Simoncelli E., Villa M., Conti F., Priori R.
Rome, Italy

PO7:117 PHYSICAL ACTIVITY LEVEL IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME

Miyamoto S.T.¹, Oliveira F.R.*², Valim V.¹, Machado K.L.L.¹, Serrano E.V.¹, Gianórdoli A.P.E.¹, Altoé L.B.¹, Noronha B.D.¹, Santos P.H.A.¹, Pedrini A.P.T.¹, Nicole N.R.S.¹, Mota J.C.¹, Rosa B.B.¹, Favarato L.F.¹, Alochio L.V.¹, Tomé W.A.¹
¹Vitória, Brazil, ²Ribeirão Preto, Brazil



POSTER

PO7:118 IMPACT OF SJÖGREN'S SYNDROME ON OCCUPATIONAL PERFORMANCE AND QUALITY OF LIFE

Cintra B.C.*¹, Marzola M.M., Carretta R.Y.D., Rocha E.M., Oliveira F.R.
Ribeirão Preto, Brazil

PO7:119 NEUROPSYCHIATRIC SJÖGREN SYNDROME: AN ATYPICAL MANIFESTATION OF ENCEPHALITIS A CASE REPORT

Navarrete Motta L.E.*¹, Ramirez J., Gutierrez J.M., Diaz M.C., Fernández Ávila D.G., Garcia Alfonso C., Bernal Macias S.
Bogotá, Colombia

PO7:122 UPDATE ON RADIOGRAPHIC EVIDENCE OF IMPLANT THERAPY IN SJÖGREN'S PATIENTS

Laing Gibbard L.*¹, Lee J.
Toronto, Canada

8. pSS AND COVID-19 INFECTION

PO8:123 A SINGLE-CENTER COVID VACCINATION EXPERIENCE IN PATIENTS WITH SJÖGREN'S SYNDROME

Horvath I.F.*¹, Nagy B., Barath S., Orosz V., Szántó A.
Debrecen, Hungary

PO8:124 MODEL IMMUNIZATION WITH CORONAVIRUS-2 VACCINES INDUCE POTENT ANTIBODY RESPONSES BUT DOES NOT AGGRAVATE LYMPHOCYTE ABNORMALITIES IN PRIMARY SJÖGREN'S SYNDROME PATIENTS

Steinmetz T., De Wolff L., Terpstra J., Visser A., Bootsma H., Kroese F.G.M., Verstappen G.*
Groningen, The Netherlands

PO8:125 IMMUNOGENICITY AND SAFETY OF CHADOX1 NCOV-19 VACCINE IN PRIMARY SJÖGREN'S SYNDROME.

Libardi Lira Machado K.L.¹, Oliveira Souza B.¹, Barbosa Beloni Lírio M.¹, Neves Burian A.P.¹, Gonçalves Rodrigues De Aguiar L.¹, Smith Sobral Vieira G.¹, Ribeiro Moulaz I.¹, Gomes M.D.P.¹, Tatiama Miyamoto S.¹, Vieira Serrano E.¹, Reis Neto E.², Teixeira-Carvalho A.³, Valim V.*¹, Monticelo O.A.², De Souza V.A.², Ferreira G.A.², Inoue Sato E.², Xavier R.², Salviato Pillegi G.², Mill J.G.¹, Assis Martins-Filho O.³
¹Vitória, Brazil, ²São Paulo, Brazil, ³Belo Horizonte, Brazil

POSTER

P08:126 SARS-COV-2 INFECTION IN 898 PATIENTS WITH SJÖGREN'S SYNDROME: CHARACTERISTICS ASSOCIATED WITH POOR OUTCOMES

Flores-Chavez A.^{*1}, Yazdany J.², Kostov B.¹, Brito-Zerón P.¹, Romão V.C.³, Armagan B.⁴, Seror R.⁵, Melchor S.⁶, Carubbi F.⁷, Priori R.⁸, Valim V.²⁰, Lawson-Tovey S.⁹, Hyrich K.⁹, Strangfeld A.¹³, Gossec L.⁵, Carmona L.⁶, Mateus E.F.³, Schaefer M.¹⁰, Hausmann J.S.¹¹, Liew J.W.¹¹, Gianfrancesco M.¹², Jacobsohn L.¹⁹, Sirotych E.¹³, Gore-Massey M.¹⁴, Sufka P.¹⁵, Bhana S.¹⁶, Grainger R.¹⁷, Wallace Z.¹⁸, Ramos-Casals M.¹, Machado P.M.¹⁹
¹Barcelona, Spain, ²San Francisco, USA, ³Lisboa, Portugal, ⁴Ankara, Turkey, ⁵Paris, France, ⁶Madrid, Spain, ⁷L'Aquila, Italy, ⁸Roma, Italy, ⁹Manchester, UK, ¹⁰Berlin, Germany, ¹¹Boston, USA, ¹²San Francisco, USA, ¹³Hamilton, Canada, ¹⁴USA, ¹⁵St. Paul, MN, USA, ¹⁶New York, USA, ¹⁷Otago Wellington, New Zealand, ¹⁸Massachusetts, USA, ¹⁹London, UK, ²⁰Vitoria, Brazil

9. EVOLVING TOPICS IN pSS THERAPY

P09:127 METFORMIN IMPROVES OBJECTIVE MEASURES OF DRY EYES AND FOCUS SCORE IN SJÖGREN'S DISEASE: A RETROSPECTIVE OBSERVATIONAL STUDY

Rasmussen A.^{*}, Scofield R.H., Grundahl K., Radfar L., Lessard C.J., Farris A.D.
Oklahoma City, USA

P09:128 SAFETY AND TOLERABILITY OF NIPOCALIMAB ADMINISTERED AT DIFFERENT RATES OF INTRAVENOUS INFUSION IN HEALTHY ADULTS: A PHASE 1 PLACEBO-CONTROLLED SINGLE-DOSE STUDY

Leu J.H.¹, Vermeulen A.², Zazzetti F.^{*3}, Ling L.E.⁴
¹Spring House, USA, ²Beerse, Belgium, ³Buenos Aires, Argentina, ⁴Cambridge, USA

P09:129 DESIGN OF A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF NIPOCALIMAB, AN FCN ANTAGONIST, IN ADULTS WITH PRIMARY SJÖGREN'S SYNDROME

Hubbard J.^{*1}, Campbell K.¹, Sivils K.¹, Hoffman R.W.¹, Lo K.H.¹, Leu J.H.¹, Liva S.G.¹, Zuraw Q.¹, Stevens A.M.¹, Berhanu A.¹, Scofield R.H.⁴, Seror R.², Wallace D.J.³
¹Spring House, USA, ²Paris, France, ³Los Angeles, USA, ⁴Oklahoma City, USA

P09:130 DYNAMICS OF US-CHANGES IN THE STRUCTURE OF SALIVARY GLANDS WITH CYCLOPHOSPHAMIDE THERAPY DURING ONE YEAR IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME

Khvan Y.^{*}, Torgashina A., Chaltsev B., Vasiliev V.
Moscow, Russian Federation

P09:131 USE OF PLATELET RICH PLASMA (PRP) IN TREATMENT OF DRY EYE SYNDROME IN THE PATIENTS WITH SJÖGREN SYNDROME: PRELIMINARY RESULTS

Capacci A., Rubortone P., Ricci F., D'Agostino M.
Rome, Italy

P09:132 QUALITY OF LIFE IN PATIENTS WITH SJÖGREN'S DISEASE TAKING SIALAGOGUES

Sankar V.^{*}, Pagni S., Singh M., Hammitt K.M., Makara M., Papas A.
¹Boston, USA, ²Reston, USA



POSTER

PO9:133 INTERFERON ASSOCIATED PROTEINS FOR MONITORING AND PREDICTION OF CLINICAL RESPONSE TO LEFLUNOMIDE/HYDROXYCHLOROQUINE COMBINATION THERAPY DEFINED BY COMPOSITE ENDPOINTS (PRELIMINARY) STAR AND CRESS

Bogers C.*¹, Hamkour S.¹, Blokland S.¹, Versnel M.A.², Leavis H.¹, Van Roon J.¹
¹Utrecht, The Netherlands, ²Rotterdam, The Netherlands

PO9:134 EFFECTS OF SIALAGOGUES TREATMENT IN SJÖGREN'S DISEASE PATIENTS

Khoury Z.*¹, Pagni S.¹, Sankar V.¹, Singh M.¹, Makara M.², Hammitt K.M.², Papas A.¹
¹Boston, USA, ²Reston, USA

PO9:135 PATIENT SATISFACTION AND IMPACT OF SALIVARY FLOW ON EFFECTIVENESS OF XEROSTOMIA PRODUCTS: PATIENT CENTERED APPROACH FOR THE MANAGEMENT OF XEROSTOMIA

Brennan M.*¹, Purdie J.¹, Stephens C.¹, Taylor Y.¹, Hammitt K.M.², Napenas J.¹, Noll J.¹
¹Charlotte, USA, ²Reston, USA

PO9:136 PERSONALIZED MEDICINE IN TREATING SJÖGREN'S SYNDROME BY TARGETING AUTOANTIGENIC EPITOPES AND HLA-DRB1*0301 ALLELE INTERACTION

Gupta S.*, Nguyen C.
Gainesville, USA

PO9:137 AQP1 GENE THERAPY CORRECTS FLUID SECRETION DEFICITS IN SJÖGREN'S DISEASE

Perez P.¹, Warner B.¹, Ji Y.¹, Afione S.¹, Pranzatelli T.¹, Beach M.¹, Khavandgar Z.¹, Grisius M.¹, Pelayo E.¹, Baer A.², Chiorini J.*¹
¹Bethesda, USA, ²Baltimore, USA

PO9:138 RITUXIMAB PREVENTS WORSENING OF B-CELL DRIVEN SALIVARY GLAND INFLAMMATION AND EXCRETORY FUNCTION IN PRIMARY SJÖGREN'S SYNDROME: RESULTS FROM THE TRACTISS TRIAL

Pontarini E.*¹, Chowdhury F.¹, Sciacca E.¹, Grigoriadou S.¹, Emery P.², Ng W.F.³, Sutcliffe N.¹, Rivellese F.¹, Tappuni A.¹, Lucchesi D.¹, Seror R.⁴, Xavier M.⁴, Porcher R.⁵, De Wolff L.⁷, Arends S.⁷, Bootsma H.⁶, Lewis M.¹, Pitzalis C.¹, Bowman S.J.⁷, Bombardieri M.¹
¹London, UK, ²Leeds, UK, ³Newcastle-upon-Tyne, UK, ⁴Paris, France, ⁵Paris Descartes, France, ⁶Groningen, The Netherlands, ⁷Birmingham, UK

10. EVOLVING TOPICS IN HEALTH POLICIES

PO10:139 HOW RARE IS PRIMARY SJÖGREN SYNDROME?

Chevet B.*¹, Chiche L.², Devauchelle-Pensec V.¹, Cornec D.¹
¹Brest, France, ²Marseille, France

POSTER

11. EVOLVING TOPICS IN COOPERATIVE RESEARCH

PO11:140 A DIAGNOSTIC ALGORITHM FOR EVALUATING CHILDHOOD SJÖGREN'S DISEASE

Stern S.M.^{*4}, Basiaga M.L.¹, Cha S.², Thatayatikom A.³, Treemarccki E.B.⁴, Randell R.⁵, Dizon B.L.⁶, Diilanni J.⁷, Tiger S.⁷, Orrock J.E.⁸, Appenzeller S.⁹, Edens C.¹⁰, Lieberman S.M.¹¹
¹Rochester, USA, ²Gainesville, USA, ³Orlando, USA, ⁴Salt Lake City, USA, ⁵Durham, USA, ⁶Bethesda, USA, ⁷Broomall, USA, ⁸Austin, USA, ⁹Campinas, Brazil, ¹⁰Chicago, USA, ¹¹Iowa City, USA

PO11:141 KEY FEATURES AT DIAGNOSIS OF PRIMARY SJÖGREN SYNDROME IN 15,652 PATIENTS: 2022 SJÖGREN BIG DATA PROJECT

Flores-Chavez A.^{*5}, Fanny Horváth I.¹⁷, Li X.¹⁸, Rasmussen A.¹⁹, Ng W.F.¹, Dong X.²⁰, Priori-Olsson P.²², Baldini C.²³, Seror R.²⁴, Bootsma H.², Armagan B.²⁵, Gottenberg J.E.⁶, Kruize A.²⁶, Hernandez-Molina G.²⁷, Paprovník S.⁷, Danda D.²⁸, Özkiziltas B.⁸, Inanc N.²⁹, Sebastian A.⁹, Bartoloni Bocci E.³⁰, Quartuccio L.³¹, Romão V.C.³², Rischmueller M.³³, Suzuki Y.³⁴, Kwok S.³⁵, Kvarnstrom M.³⁶, Solans R.⁵, Pasoto S.G.³⁷, Galisteo C.⁵, Sene D.²⁴, Moça Trevisani V.³⁷, Isenberg D.³⁸, Hofauer B.¹⁰, Shimizu T.³⁸, Nordmark G.⁴⁰, Valim V.⁴¹, Jurcut C.⁴, Carubbi F.⁴², González García A.¹², Retamozo S.⁵, Devauchelle-Pensec V.¹¹, Melchor Diaz S.¹², Gheita T.A.³, Brito-Zerón P.⁵, López-Dupla M.⁴³, Fonseca-Aizpuru E.⁴⁴, Sanchez Berna I.¹², Morel J.¹³, Giacomelli R.⁴², Atzeni F.¹⁴, Consani S.¹⁵, Vázquez M.¹⁶, Akasbi M.¹²
¹UK, ²The Netherlands, ³Cairo, Egypt, ⁴Bucharest, Romania, ⁵Barcelona, Spain, ⁶Strasbourg, France, ⁷Ljubljana, Slovenia, ⁸Ankara, Turkey, ⁹Wroclaw, Poland, ¹⁰Rechts der Isar, Germany, ¹¹Brest, France, ¹²Madrid, Spain, ¹³Montpellier, France, ¹⁴Milan, Italy, ¹⁵Montevideo, Uruguay, ¹⁶San Lorenzo, Paraguay, ¹⁷Debrecen, Hungary, ¹⁸Hefei, Anhui, China, ¹⁹USA, ²⁰Beijing, China, ²¹Rome, Italy, ²²Malmö, Sweden, ²³Pisa, Italy, ²⁴Paris, France, ²⁵Ankara, Turkey, ²⁶Utrecht, The Netherlands, ²⁷Ciudad de Mexico, Mexico, ²⁸Tamil Nadu, India, ²⁹Istanbul, Turkey, ³⁰Perugia, Italy, ³¹Undine, Italy, ³²Lisbon, Portugal, ³³Adelaide, Australia, ³⁴Kanazawa, Japan, ³⁵South Korea, Korea, Republic of Korea, ³⁶Stockholm, Sweden, ³⁷São Paulo, Brazil, ³⁸London, UK, ³⁹Nagasaki, Japan, ⁴⁰Uppsala, Sweden, ⁴¹Vitoria, Brazil, ⁴²L'Aquila, Italy, ⁴³Tarragona, Spain, ⁴⁴Asturias, Spain,

PO11:142 CD4+ CYTOTOXIC T LYMPHOCYTES (CTL) ARE PRESENT IN SJÖGREN'S DISEASE MINOR SALIVARY GLANDS AND ASSOCIATE WITH MARKERS OF EPITHELIAL CELL DAMAGE NEAR INFILTRATES

Joachims M.¹, Li C.¹, Rusbuldt J.², Fowler B.¹, Rasmussen A.¹, Grundahl K.¹, Scofield R.H.¹, Sivils K.², Lessard C.J.¹, Farris A.D.^{*1}
¹Oklahoma City, USA, ²Spring House, USA

PO11:143 PERSONALITY TRAITS CORRELATE WITH DISEASE ACTIVITY IN PRIMARY SJÖGREN'S SYNDROME

Módis L.^{*}, Aradi Z., Horvath I.F., Szántó A., Bugán A.
Debrecen, Hungary



POSTER

12. MISCELLANEOUS

PO12:144 WORLD SJÖGREN'S DAY 2021: A 3-AXIS CAMPAIGN ABOUT FATIGUE

Grosjean A.* , Stone L., Vieira A., Koelewijn-Tukker J., Bouillot C., Antonopoulou K., Oosterbaan M.
Bienne, Switzerland

PO12:149 IMPACT OF NEUROLOGICAL COMPLICATIONS ON QUALITY OF LIFE IN SJÖGREN'S

Church J.E.* , Makara M., Hammitt K.M.
Reston, USA

PO12:150 PERCEPTIONS, BEHAVIORS AND EXPERIENCES RELATED TO COVID-19 AND THE COVID-19 VACCINE: A SURVEY OF U.S.-BASED SJÖGREN'S PATIENTS

Makara M.* , Church J.E., Hammitt K.M.
Reston, USA

PO12:151 UNMET NEEDS IN RESEARCH, HOW PATIENTS CAN COLLABORATE: THE EXAMPLE OF NECESSITY

Bouillot C.*¹, Hammitt K.M.², Hjertviksten Lindland A.³, Oosterbaan M.⁴, Pincemin M.¹, Stone L.⁵

¹Paris, France, ²Reston, USA, ³Oslo, Norway, ⁴Maarsse, The Netherlands, ⁵Birmingham, UK

PO12:152 AN EMPIRICAL LINGUISTIC ANALYSIS OF THE TERMS USED FOR THE DISEASE DESCRIBED BY HENRIK SJÖGREN

Yarowsky D.¹, Mackey A.², Turner B.¹, Blanck J.¹, Hammitt K.M.³, Ramos-Casals M.⁴, Baer A.*¹

¹Baltimore, MD, USA, ²Washington, DC, USA, ³Reston, VA, USA, ⁴Barcelona, Spain

PO12:153 RECIPROCAL IMPACT OF FIBROMYALGIA ON DISEASE CHARACTERISTICS AND PHYSICAL AND PSYCHOLOGICAL DOMAINS IN SJÖGREN SYNDROME: CROSS SECTIONAL OBSERVATIONAL STUDY.

Capacci A.* , Rubortone P., Alivernini S., D'Agostino M.
Rome, Italy

PO12:155 DIAGNOSTIC UTILITY OF A SECOND MINOR SALIVARY GLAND BIOPSY IN PATIENTS WITH SUSPECTED SJÖGREN'S SYNDROME: A RETROSPECTIVE COHORT STUDY

Carvajal Alegria G.* , Depinoy T., Devauchelle-Pensec V., Jousse-Joulin S., Marhadour T., Guellec D., Marcorelles P., Pers J.O., Saraux A., Cornec D.

Brest, France

PO12:156 SJÖGREN'S AND NON-SJÖGREN SICCA IN TIMES OF CORONA

Baert-Jansen A.* , Koelewijn-Tukker J., Visser-Noordegraaf M.
Maarsse, The Netherlands

PO12:157 PATIENT ASSOCIATION IN TIMES OF CORONA

Abma A., Baert-Jansen A., Koelewijn-Tukker J.* , Oosterbaan M., Pors V.
Maarsse, The Netherlands





INFORMATION



SCIENTIFIC INFORMATION

CONGRESS PLATFORM AND VIRTUAL ACCESS

Being an hybrid event, all the sessions of the Sjögren's Symposium are live streamed through the platform <https://sjogrensymposium.livebit.it>

For the first access you will be required to enter the access code received by the Organizing Secretariat. For further log-in please create your own username and password. A chat with the Organizing Secretariat in the platform is available for assistance.

ABSTRACT BOOK

All submitted abstracts, accepted as oral presentation or poster, have been published in the Abstract Book of the Congress, in the special edition of the Clinical and Experimental Rheumatology Journal.

The abstract book is available for download from the Congress website <https://www.sjogren2022.com/>

GUIDELINES FOR CHAIRPERSONS AND SPEAKERS

- Locate your session room in due time and find yourself there at least 10 minutes before the beginning of the session to meet each other
- Respect the timing allowed to the session and to each presentation
- All presentations, discussions and questions must be in English

Audiovisual instructions

Speakers are requested to submit their presentations (16:9 format) to the slide centre at least 2 hour before the start of their session. Personal computers cannot be connected to the projectors in the session room and presentations cannot be loaded directly on the computer of the session rooms. If speakers created their presentation using a system different from Windows (such as OS MAC or Linux), they are kindly requested to provide presentations in a Windows-compatible format and to come earlier to the slide centre, in order to have enough time to solve possible compatibility issues. At the slide centre our hostess will welcome and help speakers. Experienced technicians will assist speakers in transferring the slides and make changes if needed. Slide presentations will then be uploaded to the Auditorium.

BEST PAPERS

The best posters presented will receive a prize during the Closing Ceremony. The selection will be done by the Chairs during sessions

ORAL COMMUNICATIONS

Participants presenting in oral sessions are requested to submit their presentations to the slide centre at least 2 hour before the start of their session.

CME ACCREDITATION

An application has been made to the EACCME® for CME accreditation of this event.

Attendance is monitored through a scanner device to check learner's entrance/exit each day. Attending 100% of the sessions is a main requirement to obtain credits.

Participants will receive their certificate of attendance and UEMS credit points certificate once they have filled in the evaluation form through an online system. All the information will be sent by e-mail after the congress by the Organizing Secretariat. Make sure we have your most updated email address at the Registration desk.



GENERAL INFORMATION

CONGRESS VENUE

Auditorium Antonianum
Viale Manzoni 1 - Rome (Italy)

It is located few steps away from the San Giovanni in Laterano Cathedral and the Colosseum, close to the metro-line station Manzoni and 15 min far by walking from the train station Termini.

ORGANIZING SECRETARIAT



AIM Group International - Milan Office
Via G. Ripamonti, 129 - 20141 Milan, Italy

SECRETARIAT AND REGISTRATION DESK

The on-site registration desks will be open during the following days:

- Wednesday September 7, hrs 13.30-19.00
- Thursday September 8, hrs 07.30-17.30
- Friday September 9, hrs 07.30-18.30
- Saturday September 10, hrs 08.00-14.00

ADMISSION

Participants are kindly requested to wear their badge during all congress activities. The badge will admit to the scientific sessions, coffee breaks and lunches.

OPENING CEREMONY AND WELCOME COCKTAIL

The Opening Ceremony of the Congress will be held on September 7 from hrs 18.15 in the Auditorium of the Congress Venue. A standing cocktail will follow.

COFFEE BREAKS AND LUNCHES

Coffee breaks and buffet lunches are included in the registration fee. They are served at level 1, in the congress venue.

SOCIAL DINNER

The Social Dinner (upon payment) will be held on September 9, hrs 20.00, at the Les Etoiles Restaurant. It is a panoramic restaurant located at the last floor of the Hotel Atlante, close to the Vatican district.

Address: Via Giovanni Vitelleschi, 34 - 00193 Rome.

If you paid for your seat, do not forget to pick up the invitation card at the Registration Desk. Transfer to/from the Social Dinner venue is not provided. Info on how to reach the Restaurant are available at the Registration Desk.

LANGUAGE

The official language is English. No simultaneous translation will be provided.



GENERAL INFORMATION

CUSTOMER SATISFACTION SURVEY & CERTIFICATE OF ATTENDANCE

At the end of the event, you will receive an online survey to score the main congress services. This will help us doing better in the future.

Your attendance certificate will be ready for download at the end of the survey.

SAFETY MEASURES

The Organizing Secretariat is strongly committed to deliver the safest in presence event and is constantly monitoring the global health situation.

Conference spaces are suitable to host safely all registered attendees and do comply with current public health guidance. The Organizing Secretariat Staff will constantly check the flows in the congress area to avoid any crowding.



For everyone's safety, we kindly invite all delegates to wear face masks in all conference spaces.



Hand sanitizing units are placed throughout the venue.



We are committed to ensure you get the most out of your Congress experience in a safe environment.

CLOAKROOM

Cloakroom and luggage storage facilities are available in the Congress venue

WI-FI

Free Wi-Fi is available in the Congress area.

Please connect to the network **Auditorium Antonianum** and enter the password **Sjogren2022!**

NO-SMOKING

Smoking in the meeting area is not allowed.

MOBILE PHONES

Delegates are kindly requested to set their mobile phones on silent mode in the Auditorium where scientific sessions are being held.

INSURANCE

Congress organizers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the Congress.

PRIVACY POLICY

The information on the processing of personal data in accordance with European Regulation nr. 679 of 2016 has been inserted in the Congress bags. Please consult the information sheet for full details.





TIPS WHEN IN ROME



TIPS WHEN IN ROME

Here's what you need to know when visiting Rome

**Order coffee at the bar**

Order your coffee directly at the bar to avoid paying a service charge for being served at a table, which often doubles your bill. When you enter a café, locate the cashier and place your order, then take your receipt to the bar to receive your beverage of choice. Espresso only takes a minute to enjoy so it's easy to drink it standing up.

P.S Don't order a cappuccino after noon: avoid committing one of Italy's most infamous food crimes and enjoy your frothy cappuccino before noon. Cappuccino is only suitable at breakfast (preferably paired with a *cornetto*, an Italian croissant). Hint: a caffè macchiato, an espresso with a splash of milk, is an acceptable alternative that you can order at any hour of the day without raising any eyebrows.

**Gelato is acceptable any time, any season**

Italy's longstanding customs and traditions can be difficult to navigate, but you don't have to worry about eating gelato in the colder months. Italians enjoy this treat year-round and Rome's best artisanal *gelaterie* change their flavours seasonally, so look out for juicy fruit flavours and interesting combinations with pistachios and hazelnuts.

**Get your stomach on Roman time**

Lunch between 13-14.

Aperitivo between 17-19.

Restaurants open for dinner from 19.30 - occasionally 19.00. They'll really start to fill up around 20.30-21.00.

Rome is absolutely packed with delicious food, but if you're looking for the most traditional pastas in Rome, look no further than the four dishes: *carbonara*, *pasta alla gricia*, *amatriciana*, and *cacio & pepe* are all sublime.

Don't consider your trip to Rome complete unless you've at least sampled a few bites of each!



TIPS WHEN IN ROME***Tippling is not obligatory, but it's appreciated***

Tippling has not traditionally been part of the Italian culture, as service charge is generally included in the bill as the *coperto* (cover) or breadbasket but leaving a few extra coins at the table is often appreciated. Depending on the final price of your meal, the level of service you received and the number of people in your party, you can leave anywhere from 5-10% on the table.

Italy still largely functions on a cash economy, so be sure to carry cash with you during your time in Rome. Coins, or *spicci*, are especially welcome at cafés small shops so hold on to your Euros – they're a precious commodity here.

***Buy bus tickets ahead of time***

Rome's public transportation leaves much to be desired, but if you need to take a bus in the city centre, be sure to stock up on bus tickets ahead of time because you can't buy them on the bus. You can buy tickets at any *tabaccheria* in the city, little convenient shops that are designated with a large T.

Tickets are €1.50 each, or opt for a 24-hour, 48-hour or weekly ticket for a discounted price. Tickets are valid for all forms of public transportation in Rome (bus, metro, tram and local train).

***Watch your bags***

Always be mindful of your bags on public transportation and around key tourist attractions (this is a general rule that you should use in any crowded, large city anyway). The city is very safe but petty crime is rampant, especially on crowded buses and metros. Thieves in Rome are stealthy, so always keep your bags zipped and held in front of you; wallets should ideally be tucked in your inner jacket pockets. Never leave a bag hanging off a chair at a restaurant.

***Dress modestly in church***

Rome has over 900 churches that house some of the city's most beautiful works of art, so don't miss stepping inside to marvel at their treasures, whether you're devout or not. Just be sure to dress appropriately to enter these holy spaces: women's shoulders should be covered, and skirts should hit at or below the knee, while men should wear pants or shorts that extend to the knees. Linen pants are a great option for the summer and a scarf is a perfect last-minute cover-up if you're wearing a tank top.



TIPS WHEN IN ROME



Don't try to see the Vatican Museums and Colosseum on the same day

It's an absolutely exhausting endeavor, and won't leave time for seeing much of anything else that day in Rome!



Book tickets and tours for popular attractions in advance

It requires a bit of extra planning but honestly makes for a better experience, too.



How to say...

When you enter a shop or a restaurant you can say "buongiorno" until lunchtime and "buonasera" in the afternoon and evening; when you leave, you should say "arrivederci."

Grazie = thank you

Per favore = please

Prego = you're welcome

When you need your bill at the restaurant just stay at the table and say to the waiter "Mi porta il conto per favore?"





AUTHORS INDEX



A

Aarebrot A.K. 32
 Abacar K.Y. 39, 41
 Abma A. 47
 Ademaglu Z. 38
 Afione S. 45
 Aguiar F. 33
 Akasbi M. 37, 41, 46
 Akpek E.K. 17
 Alarcón-Riquelme M.E. 31, 33
 Aleksandrova E. 35
 Alessandri C. 41
 Alevizos I. 25
 Alivernini S. 35, 47
 Allenbach Y. 40
 Alochio L.V. 42
 Altingöz E.N. 39
 Altoé L.B. 42
 Alunno A. 41
 Alves Ribeiro L. 40
 Anaya Cabrera J.M. 16
 Andronikou V. 33
 Anjum J. 31
 Antonopoulou K. 47
 Appel S. 28, 32
 Appenzeller S. 46
 Aqrabi A.L. 29
 Aradi Z. 40, 46
 Arca K. 39, 41
 Arends S. 20, 36, 39, 45
 Armagan B. 37, 44, 46
 Asam S. 32
 Assan F. 40
 Assis Martins-Filho O. 43
 Atturo F. 42
 Atzeni F. 37, 46
 Aue A. 29
 Avey S. 34
 Axtell R.C. 38

B

Baer A. 11, 17, 45, 47
 Baert-Jansen A. 47
 Bagacean C. 28
 Baker J. 36
 Baker M.C. 42
 Baldini C. 11, 13, 20, 24, 28, 33, 35,
 37, 41, 46
 Bandeira M. 32, 38, 41
 Barath S. 43
 Barbati C. 30, 42
 Barbosa Beloni Lírio M. 43
 Barnes M. 14
 Barone F. 32
 Baron G. 39
 Barrio Cortes J. 17, 20
 Bartels C. 40
 Bartoloni Bocci E. 18, 28, 33, 41, 46

Basiaga M.L. 46
 Batani V. 37
 Beach M. 45
 Bechara R. 29
 Bekker C. 28
 Bellone M. 37
 Benveniste O. 40
 Ben-Youssef A. 36, 37
 Berardicurti O. 32
 Berg M. 28
 Bergum B. 28
 Berhanu A. 44
 Bernal Macias S. 39, 43
 Berrouiquet S. 37
 Bettacchioli E. 33
 Beydon M. 30, 34
 Bhana S. 44
 Bharaj T. 28
 Bhaskaran S. 31
 Bianconi V. 28
 Bikker F. 30
 Bisaralli R. 36
 Blake W. 10
 Blanchet O. 30
 Blanck J. 47
 Bloch D. 42
 Blokland S. 28, 45
 Bogers C. 45
 Bombardieri M. 9, 33, 39, 45
 Bombardieri S. 8, 20
 Bonelli F. 37
 Bonet D. 34
 Boni A. 32
 Bootsma H. 12, 14, 28, 29, 30, 31,
 33, 36, 37, 39, 43, 45, 46
 Borda Samper C. 39
 Bordron A. 28
 Borge H. 28, 29
 Bouillot C. 47
 Bowman S.J. 20, 29, 31, 32, 33,
 39, 45
 Bracaglia C. 32
 Brahim I. 36
 Brennan M. 31, 45
 Brith B. 32
 Brito I. 33
 Brito-Zerón P. 17, 19, 37, 41, 44, 46
 Brokstad K. 28
 Broner J. 40
 Brun J.G. 28, 32
 Bruno D. 35
 Bruxvoort C. 29, 31
 Bruyn G.A.W. 24, 38
 Buckley C.D. 32
 Bueno I.B. 38
 Bugán A. 46
 Buoncuore G. 30, 42
 Burmeister J. 33
 Butt M. 30

C

Cafaro G. 15, 28
 Caiello I. 32
 Campbell K. 44
 Camus M. 39
 Capacci A. 44, 47
 Carmona L. 44
 Carretta R.Y.D. 43
 Carsons S.E. 42
 Carteron N.L. 42
 Carubbi F. 37, 41, 44, 46
 Carvajal Alegria G. 36, 37, 47
 Cathleen P. 31
 Cavett J. 29, 31
 Celia A.I. 41
 Chabrun F. 30
 Chakraborty S. 41
 Chaltsev B. 34, 35, 39, 44
 Chambers A. 31
 Chao De La Barca J. 30
 Cha S. 46
 Chatzis L. 12, 13, 31, 33, 35
 Chevet B. 45
 Chiara B. 40
 Chiche L. 45
 Chiorini J. 45
 Chivasso C. 28
 Chondrogiannis E. 33
 Chouhan S. 36
 Chowdhury F. 45
 Chriti N. 30
 Church J.E. 47
 Cimsit C. 38
 Cimsit C. 38
 Cintra B.C. 43
 Ciurtin C. 29, 30
 Cochener B. 37
 Cochner-Lamad B. 36
 Colafrancesco S. 10, 19, 30, 32, 33,
 38, 41, 42
 Cole J. 41
 Conrad L. 28
 Consani C. 37
 Consani S. 46
 Conti F. 17, 30, 38, 41, 42
 Conze P. 36
 Cornec D. 28, 30, 33, 36, 37, 39,
 40, 45, 47
 Cosentini E. 28
 Courtois-Communier E. 40
 Coutinho G. 38
 Cox R. 28
 Croft A.P. 32
 Curcio G. 42

D

Dagna L. 37
 D'Agostino C. 28
 D'Agostino M. 38, 44, 47



- Danda D. 37, 46
Danielides S. 42
Davies R. 32
De Benedetti F. 32
Deboo A. 42
Dejaco C. 24
Delli K. 24, 36
Del Papa N. 16
Delporte C. 28, 33
De Marchi G. 40, 41
Depinoy T. 47
Desmoulins F. 30, 36
De Sousa E. 42
De Souza V.A. 43
Desvaux E. 13
Devauchelle-Pensec D. 37
Devauchelle-Pensec V. 28, 30, 33,
34, 36, 37, 39, 40, 41, 45, 46, 47
De Vita S. 8, 12, 17, 32, 33, 34, 35,
38, 40, 41
De Wolff L. 36, 39, 43, 45
Diaz M.C. 39, 43
Di Franco M. 42
Diilanni J. 46
Di Mario C. 35
Direnzo D. 36
Direskeneli H. 39
Dizon B.L. 46
Donati V. 33, 35
Dongre H. 29
Dong X. 37, 46
Doria A. 16
Dörner T. 12, 16, 19, 29, 33
Dreher M. 32
Dubost J.J. 34
Dueymes M. 28, 33
Duffau P. 40
Dulin M. 10
- E**
Edens C. 46
Elefante E. 33, 40
El Zawahry O. 42
Emery P. 45
Erol Kalkan K. 38
Espitia A. 40
Estes J. 36
Esteves Marques R. 38
Eurico Fonseca J. 32
Exarchos T.P. 14, 33, 35
- F**
Fabro C. 32, 35, 41
Fanin R. 35
Fanny Horváth I. 46
Farris A.D. 31, 38, 44, 46
Favarato L.F. 42
Feijoo-Masso C. 41
Fenando A. 36
Fernández Ávila D.G. 39, 43
Ferracioli G. 12, 35
Ferrari G. 37
Ferreira G.A. 43
Ferro F. 24, 33, 35, 36
Filer A. 32
Filipovic N. 28, 33
Finzel S. 38
Fisher B.A. 11, 32, 36, 39
Flint J. 32
Flores-Chavez A. 37, 41, 44, 46
Florian K. 32
Fonseca-Aizpuru E. 37, 46
Fonseca J.E. 38, 40
Fonzetti S. 33
Fortune F. 39
Fotiadis D.I. 14, 33, 35
Foulquier N. 37
Fowler B. 46
Fox R.I. 18, 42
Franks C. 34
Frémont G. 18
Fromreide S. 28, 29
Fulvio G. 13, 33
- G**
Gaffney P. 29, 31
Gaiduk I. 35
Gajdanowicz P. 30
Galisteo C. 37, 46
Gallay L. 40
Galli M. 19
Galtung H. 29
Gandolfo S. 33
García Alfonso C. 43
Gardner D.H. 32
Gattamelata A. 24, 30, 38, 41, 42
Georgel L. 37
Georgescu C. 38
Gergely P. 39
Gerli R. 8, 16, 28, 33, 37, 41
Gheita T.A. 37, 46
Giacomelli R. 33, 37, 41, 46
Gianfrancesco M. 44
Gianórdoli A.P.E. 42
Giardina F. 30, 38, 41, 42
Gioia C. 42
Giovannini I. 24, 32, 34, 35, 38, 40
Gomes M.D.P. 43
Gonçalves A.I. 38
Gonçalves M.J. 38
Gonçalves Rodrigues De Aguiar
L. 43
González García A. 37, 46
González Rojas B.J. 39
Goodman B. 39, 41, 42
Gordeev A. 41
Gore-Massey M. 44
Gorodetskiy V. 35
Gossec L. 44
Gottenberg J.E. 11, 34, 37, 39, 46
Goules A.V. 11, 13, 14, 21, 31, 33,
35
Grainger R. 44
Grasland A. 40
Gravey M. 37
Gremese E. 35
Grigoriadou S. 45
Grisius M. 45
Grosjean A. 47
Grundahl K. 44, 46
Guellec D. 36, 37, 40, 47
Gupta S. 45
Guthridge J. 38
Gutierrez Davila J.M. 39
Gutierrez J.M. 43
- H**
Hachulla E. 34, 40
Hakan E. 38
Hamkour S. 19, 45
Hammenfors D. 32, 36
Hammitt K.M. 20, 42, 44, 45, 47
Han J.H. 36
Hanova P. 38
Harris-Lewis V. 31
Hassanein D. 42
Hausmann J.S. 44
Hayem G. 40
Helgesen Y. 28
Helgesen Y. 28
Hemon P. 31, 37
Hernandez-Molina G. 37, 41, 46
Hetzel S. 40
Higham J. 32
Hillen M. 28
Hillion S. 30
Hinrichs A. 28, 30
Hjertviksten Lindland A. 47
Hoccar A. 24, 34, 38
Hofauer B. 36, 37, 41, 46
Hoffman R.W. 44
Hoffland I. 30
Holley A. 42
Hong-Ki M. 36
Horvath I.F. 43, 46
Houssais C. 40
Hubbard J. 44
Hueber W. 39
Huijser E. 34
Hu X. 34
Hyrich K. 44
- I**
Iagnocco A. 38
Iannizzotto V. 32
Iannuccelli C. 42
Ilgen U. 38

Illei G. 20
Inanc N. 19, 37, 38, 39, 41, 46
Inoue Sato E. 43
Isenberg D. 37, 46
Isola M. 35
Izzo R. 30, 38, 41, 42

J
Jabari D. 36
Jacobsohn L. 44
James J.A. 29, 31, 38
Jamin C. 28, 37
Jason D.T. 32
Ji Y. 45
Joachims M. 29, 31, 46
Johan S. 41
Jonsson M. 17, 36
Jonsson R. 28, 29, 31, 32, 33
Joshi A.M. 32
Jousse-Joulin S. 24, 28, 34, 36, 37, 38, 40, 47
Jupudi A.A. 10
Jurcut C. 37, 46
Jury E. 30
Jury L. 29
Jutel M. 30

K
Kachaner A. 36
Kalatzis F. 33
Kapsogeorgou E. 9
Kapusuz A. 39
Karacayli U. 39
Karanastasis E. 33
Karfonta B. 31
Keen H. 38
Khatri B. 29, 31, 38
Khavandgar Z. 45
Khmelinskii N. 32, 38
Khoury Z. 45
Khvan Y. 34, 35, 39, 44
Kim H. 36
Kim J. 36
Koelewijn-Tukker J. 47
Koelsch K.A. 29, 31, 38
Kokosadze N. 35
Kolijn P.M. 34
Kostov B. 44
Kourou D.K. 33
Kroese F.G.M. 9, 28, 29, 30, 31, 36, 43
Kruize A. 28, 30, 37, 46
Kurien B. 29, 31
Kurien B.T. 31
Kvarnstrom M. 37, 46
Kwok S. 37, 46

L
Labetoulle M. 37
Lacout C. 30
Lafeber F. 28, 30
Laing Gibbard L. 43
Lamard M. 36
Lamotte C. 36
Lança M. 38
Langerak A.W. 34
Lang S. 41
La Rocca G. 33
Larroche C. 34
Lavigne C. 30, 34
Law B. 12
Lawrence C. 38
Lawrence S. 31
Lawson-Tovey S. 44
Leavis H. 28, 30, 45
Lee J. 36, 43
Le Guern V. 34, 40
Lessard C.J. 9, 10, 15, 21, 29, 31, 38, 44, 46
Leszczuk J. 34
Letourneur F. 28
Leu J.H. 44
Lewis M. 45
Lewis V. 31
Liaaen Jensen J. 29
Libardi Lira Machado K.L. 43
Li C. 46
Lieberman S.M. 46
Liefers S.C. 29
Liew J.W. 44
Ling L.E. 44
Lino A. 29
Lishchuk I. 33
Liu G. 34
Liva S.G. 44
Li X. 37, 46
Lizano M. 31
Lo K.H. 44
Longhino S. 32, 33, 35, 38, 40, 41
Longobardi S. 38
Lontoc T. 34
Lopes A. 28
Lopes P. 38
Lopez-Davis C. 38
López-Dupla M. 37, 41, 46
Lorenzon M. 24
Lozac H.P. 30
Lucchesi D. 45
Luczak A. 30

M
Machado K.L.L. 42
Machado P.M. 44
Macieira C. 38
Mackey A. 47
Madej M. 30

Makara M. 42, 44, 45, 47
Mancini P. 42
Mandel S. 42
Manfrè V. 15, 32, 33, 34, 35, 38, 40, 41
Mannarino M.R. 28
Manoussakis M. 13
Marasco E. 32
Marcelli C. 34
Marcourelles P. 47
Marec N. 30
Marhadour T. 37, 40, 47
Mariampillai K. 40
Mariani L. 42
Marianne X. 12, 21, 28, 29, 30, 31, 34, 36, 39, 40, 41
Marinoska T. 32
Marrani E. 18
Martin-Gutierrez L. 29, 30
Martins A.L. 38
Martis N. 40
Marzola M.M. 43
Masaoutis C. 35
Mastromanno L. 30, 38, 41, 42
Mateus E.F. 44
Matianova E. 41
Matteo V. 32
Mattii L. 28
Mavragani C. 14
Mavragani P.C. 33
May T. 33
Mccoy S. 40
McCoy S. 15
Medeiros J. 40
Melchor Diaz S. 46
Melchor Diaz S. 37
Melchor S. 44
Meyer A. 40
Milic V. 36
Mill J.G. 43
Miyamoto S.T. 42
Moawad P. 42
Moça Trevisani V. 37, 46
Möckel T. 32
Módis L. 46
Monticelo O.A. 43
Morel J. 37, 46
Morel M. 28
Morena Bueno Silva L. 38
Moroni L. 37
Morris M. 34
Mosca K. 34
Mosca M. 18, 21, 33
Moscato S. 28
Mossel E. 36
Mota J.C. 42
Mougeot F. 31
Mougeot J. 31
Mourits M. 31



Mouterde G. 36
Moutsopoulos H.M. 33, 35
Muhammad S.S. 28
Mulleman D. 40
Mumcu G. 38, 39
Murphy P. 34

N

Nagel A. 29, 31
Nagy B. 43
Nagy G. 40
Nakshbandi U. 29
Nanda R. 36
Napenas J. 45
Naredo E. 38
Navarini L. 24
Navarrete Motta L.E. 39, 43
Navarro Garcia I.C. 33
Navarro I. 33, 40
Nayar S. 16, 32
Nettey O. 29
Neves Burian A.P. 43
Nguyen C. 19, 31, 45
Ng W.F. 14, 29, 31, 32, 33, 37, 41, 45, 46
Nicolai R. 32
Nicole N.R.S. 42
Nimwegen J. 31
Noaieh G. 36, 42
Nocturne G. 9, 16, 28, 29, 30, 34, 36, 40
Noll B. 31
Noll J. 31, 45
Nordmark G. 29, 31, 37, 46
Noronha B.D. 42
Noury J. 40
Novikov A. 35, 36

O

Olie L. 36
Oliveira F.R. 38, 42, 43
Oliveira M.C. 38
Oliveira Souza B. 43
Olsson P. 37, 46
Omdal R. 29, 31
Oosterbaan M. 47
Orlandi M. 41
Orosz V. 40, 43
Orrock J.E. 46
Ozkiziltas B. 37, 46

P

Paglioni A. 35
Pagni S. 44, 45
Palshina S. 35, 36
Pandis I. 34
Pandit A. 28
Papas A. 15, 41, 44, 45
Paprovnik S. 37, 46

Paraskevi V. 35
Pardo G. 38
Paris D. 33
Park A. 42
Pascaud J. 28, 29
Pasoto S.G. 37, 41, 46
Patel C. 34
Pavlakis P.P. 42
Peckham H. 29
Pedrini A.P.T. 42
Pegolo E. 32, 35
Pelayo E. 45
Peng J. 29, 30
Pérez M.M. 33
Perez P. 45
Perret J. 28
Perricone C. 28
Perrodeau E. 39
Pers J.O. 11, 21, 28, 30, 31, 33, 37, 47

Petrovic A. 32
Pezoulas V.C. 33, 35
Pharaoh G. 31
Pincemin M. 47
Pineda C. 38
Pinheiro Lopes A. 10
Pinto J. 38
Pires Marafon D. 32
Pirro M. 28
Pitzalis C. 45
Pochard P. 28
Pontarini E. 45
Ponzoni M. 8, 35
Porcher R. 39, 45
Porchet E. 30
Pors V. 47
Portanova G. 42
Poveda-Gallego A. 32
Pranzatelli T. 45
Prencipe G. 32
Pringle S. 28, 29, 30
Priori R. 18, 30, 33, 37, 38, 41, 42, 44, 46
Probatova N. 35
Pucino V. 32
Purdie J. 45

Q

Quartuccio L. 14, 19, 32, 33, 34, 35, 37, 40, 41, 46
Quellec G. 36
Quééré B. 16, 36, 40

R

Rabault R. 40
Radfar L. 29, 31, 38, 44
Radic M. 18
Radstake T. 28
Radziszewska A. 29

Radziszewski M. 31
Ragab G. 42
Rajão Martins F. 33
Ramirez J. 43
Ramos-Casals M. 20, 21, 33, 37, 41, 44, 47
Randell R. 46
Rasmussen A. 29, 31, 37, 38, 44, 46
Rath P.D. 36
Rauz S. 32
Reed J. 12
Reis Neto E. 43
Retamozo S. 17, 19, 37, 41, 46
Reynier P. 30
Reynosos E. 34
Ribeiro Moulaz I. 43
Ricci F. 44
Ricucci I. 28
Richards A. 32
Rischmueller M. 29, 31, 37, 46
Ritter J. 29
Rivellesse F. 45
Rivière E. 28, 29
Rizzo M.T. 32, 33, 35, 41
Robinson G. 30
Robles A. 41
Rocca J. 34
Rocha E.M. 43
Rodionova E. 35, 36
Rodrigues M. 33
Rodrigues W. 38
Roh J. 36
Romão V.C. 32, 37, 38, 40, 41, 44, 46
Rönblom L. 29, 31
Rontogianni D. 35
Roon J.V. 39
Rosa B.B. 42
Rubortone P. 44, 47
Rusbuldt J. 46

S

Safonova T. 35
Sahu A.K. 36
Salvado F. 38
Salviato Pillegi G. 43
Sánchez-Berná I. 37, 46
Sandhya P. 33
Sanges S. 40
Sankar V. 44, 45
Santos P.H.A. 42
Saroux A. 33, 36, 37, 40, 47
Sarka G. 42
Sarkar I. 32
Sarzi Puttini P. 18
Sawicki B. 41
Schaefer M. 44
Schmidt J. 34

Schmidt W.A. 38
Schrezenmeier E. 29
Schwartz A. 32
Sciacca E. 45
Schofield R.H. 29, 31, 38, 42, 44, 46
Scott C.A. 35
Scailler Y. 31, 37
Sebastian A. 30, 37, 46
Sebastian M. 30
Seghieri C. 20
Sene D. 37, 46
Seror R. 14, 30, 34, 36, 37, 39, 41, 44, 45, 46
Serrano D. 34
Serrano E.V. 42
Shahnawaz Soyfoo M. 33
Shah S. 36
Shalabi H. 29
Shamma R. 42
Shen Y. 31
Shiboski C.H. 20, 21
Shimizu T. 37, 46
Shornikova L. 36
Shornikova N. 35
Silvério António M. 38
Silvério António M. 32, 40
Simão R. 38
Simard G. 30
Simoncelli E. 30, 38, 41, 42
Singh M. 41, 44, 45
Sirotych E. 44
Sivits K. 25, 29, 31, 33, 44, 46
Sivits K.L. 46
Skarstein K. 28, 29
Skopouli F. 33, 35
Smith C. 32
Smith Sobral Vieira G. 43
Sokol E. 34, 35
Solans R. 37, 46
Solberg S.M. 32
Spijkervet F. 28
Spijkervet F.K. 29
Stano S. 32
Stefanski A. 29
Steinmetz T. 43
Stel A. 24, 36
Stephens C. 45
Stergiou I. 35
Stern S. 42
Stern S.M. 46
Stevens A.M. 44
Stolarczyk A. 29, 31
Stone L. 47
Strangfeld A. 44
Sufka P. 44
Sung-Eun C. 36
Sutcliffe N. 45
Suzuki Y. 37, 46

Szántó A. 37, 40, 43, 46
Szelinski F. 29

T
Taborelli M. 34
Tappuni A. 45
Tatiana Miyamoto S. 43
Tatli I. 39
Taylor K. 10
Taylor Y. 45
Teixeira-Carvalho A. 43
Teodósio A. 32
Terpstra J. 43
Terslev L. 38
Tessner K. 29, 31
Thatayatikom A. 46
Thornburg T. 31
Tiger S. 46
Tison A. 30, 33, 40
Toffolutti F. 34
Tolusso B. 35
Tomé W.A. 42
Tommasini A. 17
Torgashina A. 34, 35, 39, 41, 44
Tornaas S. 28
Torsten W. 33
Treemarcki E.B. 46
Treppo E. 34, 40
Tsaliqi M. 29
Tsao B. 29
Tsiknakis M. 33
Türe-Özdemir F. 39
Turner B. 47
Turner J.D. 32
Tzioufas A.G. 11, 12, 17, 21, 31, 33, 35

U
Urbanski G. 11, 30

V
Valim V. 37, 42, 43, 44, 46
Valstar M. 30
Van Daele P.L. 34
Van Der Tuuk K. 31
Van Der Vegt B. 29, 30
Van Ginkel M.S. 29
Van Ginkel M.S. 13
Van Helden-Meeuwse C.G. 34
Van Kempen L. 31
Van Nimwegen J. 36
Van Remmen H. 31
Van Roon J. 28, 30, 33, 45
Vanwormer J. 40
Van Zuiden G. 36
Varadhachary A. 42
Varriano V. 35
Varvarigou T. 33
Vasiliev V. 34, 35, 36, 44


Vázquez M. 37, 46
Venetsanopoulou A. 33
Ven K. 34
Verizhnikova Z. 34
Vermeulen A. 44
Versnel M.A. 9, 34, 45
Verstappen G. 31, 36, 43
Verstappen G.M. 9
Vieira A. 20, 47
Vieira Serrano E. 43
Villa M. 30, 38, 41, 42
Visser A. 31, 43
Visser-Noordegraaf M. 47
Vissink A. 11, 28, 29, 30, 36
Vitali C. 19
Vittecoq O. 34
Vogel W. 30
Voigt A. 31
Votis K. 33
Voulgarelis H. 12
Voulgarelis M. 35

W
Wahadat M.J. 34
Wahren-Herlenius M. 29, 31
Wallace D.J. 42, 44
Wallace Z. 44
Warner B. 29, 31, 45
Wharen-Herlenius M. 9
Wiland P. 30
Wiley M. 29, 31
Witte T. 9, 29, 31
Wren J.D. 38

X
Xavier M. 33, 45
Xavier R. 43

Y
Yarowsky D. 47
Yay M. 39
Yazdany J. 44
Yenisoy Y. 39
Yu S. 41

Z
Zabotti A. 11, 12, 24, 32, 34, 35, 38, 40
Zaja F. 35
Zampeli E. 33
Zandonella Callegher S. 38
Zazzetti F. 44
Zemelka-Wiacek M. 30
Zeng W. 13
Zhang S. 30
Zindy E. 28
Zuraw Q. 44



7110
SEPTEMBER
2022

15TH
ROME

INTERNATIONAL SYMPOSIUM ON
Sjögren's
Syndrome

SPONSORS ACKNOWLEDGEMENT

Platinum Sponsor



Gold Sponsors



Silver Sponsor



Supporters





7 | 10
SEPTEMBER
2022

15TH ROME

INTERNATIONAL SYMPOSIUM ON

Sjögren's Syndrome



ORGANIZING SECRETARIAT



AIM Group International – Milan Office

Via G. Ripamonti, 129 – 20141 Milan, Italy

Info: sjogren2022@aimgroup.eu

Registrations: sjogren2022.reg@aimgroup.eu

Abstract: sjogren2022.abs@aimgroup.eu